Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
[COMPANY_009] Clinical Program 
Manager: 
[COMPANY_009] Medical Monitor: 
Clinical Study Director: 
Protocol Version/Date: [!'J GI LEAU 
CLINICAL STUDY PROTOCOL 
A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate 
Emtricitabine/f enofovir Alafenamide (F/f AF) in HIV-[ADDRESS_1280551] 
Foster City, CA [ZIP_CODE] 
111851 
2015-001339-19 
[STUDY_ID_REMOVED] 
HIV-1 
GS-US-311-1269 
Name: 
[CONTACT_10880]: 
Fax: 
Name: 
[CONTACT_10880]: 
Fax: 
Name: 
[CONTACT_10880]: 
Mobile: 
Fax: 
Original: 
Amendment 1: 
Amendment 1.1 (South Africa): 
Amendment 2: [[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[[COMPANY_003] 
[ADDRESS_1280552] or Independent Ethics Committee. The information is only to be used by [CONTACT_222184]. 
You will not disclose any of the information to others without written authorization from 
[COMPANY_009] Sciences, Inc., except to the extent necessary to obtain informed consent from those 
persons to whom the drug may be administered. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280553] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 15
1. INTRODUCTION .............................................................................................................................................. 19
1.1. Background ............................................................................................................................................ 19
1.2. Tenofovir Alafenamide (TAF, GS -7340) ............................................................................................... 21
1.2.1. General Information ............................................................................................................. 21
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 22
1.2.3. Nonclinical Pharmacokinetics .............................................................................................. 22
1.2.4. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) 
or Fixed -Dose Combination (FDC) emtricitabine/tenofovir alafenamide 
(F/TAF) ................................................................................................................................ 22
1.3. Emtricitabine (FTC, Emtriva®).............................................................................................................. 23
1.4. Rationale for This Study ........................................................................................................................ 24
1.5. Rationale for Dose Selection .................................................................................................................. 24
1.5.1. F/TAF Dose in Adolescents 12 to < 18 years of Age Weighing ≥ 35 kg ............................. 24
1.5.2. F/TAF Dose in Children 6 to < 12Years of Age Weighing ≥ 25 kg and 
2to<12Years of Age Weighing 17 to < 25 kg .................................................................. 25
1.5.3. Dosing in Cohorts 3 (2 to < 6 Years) and 4 (1 Month to < 2 Years) .................................... 28
1.6. Risk/Benefit Assessment for the Study .................................................................................................. 28
1.7. Com pliance ............................................................................................................................................ 28
2. OBJECTIVES ..................................................................................................................................................... 29
3. STUDY DESIGN ................................................................................................................................................ 30
3.1. Primary Endpoints .................................................................................................................................. 30
3.1.1. Secondary Endpoints ............................................................................................................ 30
3.2. Study Design .......................................................................................................................................... 30
3.2.1. Cohort 1 (Adolescents 12 to < 18 years, ≥ 35 kg) ................................................................ 31
3.2.2. Cohorts 2, 3, and 4 ............................................................................................................... 31
3.2.3. Study Procedures and Frequency for All Subjects (All Cohorts and 
Parts Aand B) ...................................................................................................................... [ADDRESS_1280554] Selection ............................................................................................ 37
4.2. Inclusion Criteria .................................................................................................................................... 37
4.3. Exclusion Criteria ................................................................................................................................... 39
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 41
5.1. Enrollment .............................................................................................................................................. 41
5.2. Description and Handling ....................................................................................................................... 41
5.2.1. Form ulations ......................................................................................................................... 41
5.2.2. Packaging and Labeling ....................................................................................................... 42
C
F/TAF
Protocol GS -US-311-[ADDRESS_1280555] [ZIP_CODE].2.3. Storage and Handling ........................................................................................................... 42
5.3. Dosage and Administration .................................................................................................................... 43
5.3.1. Cohort 1 (12 years to < 18 years, ≥ 35 kg) ........................................................................... [ADDRESS_1280556] Enrollment and Treatment Assignment ..................................................................................... 46
6.2. Pretreatment Assessments ...................................................................................................................... 46
6.2.1. Screening Visit ..................................................................................................................... 46
6.2.2. Baseline/Day 1 Assessments ................................................................................................ 48
6.3. Treatment Assessment s through 48 Weeks (Weeks 1 (Day 7) − 48) ..................................................... 50
6.4. Early Study Drug Discontinuation (ESDD) ........................................................................................... [ADDRESS_1280557] Week 48 Assessments (every 12 w eeks) ........................................................................................ 58
6.7. Bone Evaluations ................................................................................................................................... 60
6.8. Bone and Renal Safety Evaluations ....................................................................................................... 60
6.10.Virologic Failure and Management of Virologic Rebound .................................................................... 61
6.10.1. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -1 in Absence of Confirmed 
Virologic Failure .................................................................................................................. 62
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 63
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 63
7.1.1. Adverse Events ..................................................................................................................... 63
7.1.2. Serious Adverse Events ........................................................................................................ 63
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 64
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 64
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 64
7.2.2. Assessment of Severity ........................................................................................................ 65
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 65
7.4. [COMPANY_009] Reporting Requirements ............................................................................................................. 67
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serio us Adverse Events .......................................................................................................................... 68
7.5.1. Toxicity Management ........................................................................................................... 68
7.5.2. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 68
7.5.3. Grades 3 Laboratory Abnormality or Clinical Event ........................................................... 68
7.5.4. Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 69
7.5.5. Management of Hyperbilirubinemia in Patients Receiving Ritonavir 
Boosted Atazanavir .............................................................................................................. 69
7.6. Special Situations Reports ...................................................................................................................... 70
7.6.1. Definitions of Special Situations .......................................................................................... 70
7.6.2. Instructions for Reporting Special Situations ....................................................................... 70
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 72
8.1. Analysis Objectives and Endpoints ........................................................................................................ 72
8.1.1. Analysis Objectives .............................................................................................................. 72
8.1.2. Primary Endpoints ................................................................................................................ 72
8.1.3. Secondary Endpoints ............................................................................................................ 72
CCI
CCI
F/TAF
Protocol GS -US-311-[ADDRESS_1280558] (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... [ADDRESS_1280559] Accountability and Return ............................................. 83
9.1.8. Inspections ............................................................................................................................ 83
9.1.9. Protocol Compliance ............................................................................................................ 83
9.2. Sponsor Responsibilities ........................................................................................................................ 84
9.2.1. Protocol Modifications ......................................................................................................... 84
9.2.2. Study Report and Publications ............................................................................................. 84
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 84
9.3.1. Payment Reporting ............................................................................................................... 84
9.3.2. Access to Information for Monitoring .................................................................................. 85
9.3.3. Access to Information for Auditing or Inspections .............................................................. 85
9.3.4. Study Discontinuation .......................................................................................................... 85
10. REFERENCES ................................................................................................................................................... 86
11. APPENDICES .................................................................................................................................................... 88
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 89
Appendix 2. Study Procedures Table .......................................................................................................... 90
Appendix 3. Management of Clinical and Laboratory Adverse Events ...................................................... 94
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 95
Appendix 5. Pregnancy Precautions, Definition for Female of Childbea ring Potential, and 
Contraceptive Requirements ................................................................................................. 115
F/TAF
Protocol GS -US-311-[ADDRESS_1280560] OF IN -TEXT TABLES
Table 1-1. TAF AUC upon Co -administration of TAF (10 or 25 mg) with 3rdAgent in Adults ............. 23
Table 1-2. Pediatric F/TAF Dosing and Tablet Strength by [CONTACT_350129] .............................................. 25
Table 4-1. Prohibited Medication w hile on Study ................................................................................... 40
Table 5-1. Cohort 1 Dosing Recommendation for F/TAF in combination with 3rdARV Agents ........... 43
Table 5-2. Cohorts 2, 3, and 4 Dosing Recommendations for F/TAF ..................................................... [ADDRESS_1280561] OF IN -TEXT FIGURES
Figure 1-1. Predicted TAF AUC in Children Following Administration of F/TAF 200/25 mg or 
120/15 mga,b,c.......................................................................................................................... 26
Figure 1-2. Predicted TFV AUC in Children Following Administration of F/TAF 200/25 mg or 
120/15 mga,b,c.......................................................................................................................... 27
Figure 3-1. Study Schema ......................................................................................................................... 34
Figure 6-1. Virologic Rebound Schema .................................................................................................... 62
F/TAF
Protocol GS -US-311-[ADDRESS_1280562]
Foster City, CA [ZIP_CODE]
Study Title : A Phase 2/3, Open- Label, Multi -Cohort Switch Study  to Evaluate 
Emtricitabine/Tenofovir Alafenamide (F/TAF )in HIV -1 Infected 
Children and Adolescents Virologically  Suppressed on a 
2-NRTI -Containing Regimen
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:[PHONE_13692]-001339 -19
[STUDY_ID_REMOVED]
Study Centers Planned: Approximately  25centers globall y.
Objectives: The primary objective sof this study  are:
To evaluate the pharmacokinetics (PK) of tenofovir alafenamide 
(TAF) and confirm the TAF dose in HIV -
1 infected children and 
adolescents virologicall y suppressed on a 2-NRTI -containing 
regimen
To evaluate the safet y and tolerability  ofemtricitabine/tenofo vir 
alafenamide ( F/TAF )through Week 24
The secondary  objectives of this study are: 
To evaluate the PK of tenofovir (TFV) and emtricitabine ( FTC)
To evaluate the safet y, tolerability ,and efficacy  of F/TAF 
through Week 48
Study Design: Open -label, multi -cohort switch study  to evaluate the PK , safet y, and 
efficacy  ofF/TAF in HIV -1 infected children ( 1 month to <12years) 
and adolescents (12 to<18 y ears) who are virologically  suppressed 
(HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL  for at least 6 consecutive months) on a
stable 2-NRTI -containing regimen .
A minimum of 100subjects age d1 month to < 18 y ears of either sex 
will be enrolled as follows:
Cohort 1 ( adolescents 12 to < 18 years , ≥ 35 kg ):
All subjects in Cohort 1 (n =25) will switch their current 
2-NRTI -containing regimen to F/TAF while continuing their
3rdantiretroviral (ARV) agent through 48weeks. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280563] 2017An intensive PK (IPK) evaluation will be conducted at the Week 2
visit. TAF dose confirmation will be established if the exposure is 
comparable to that associated with efficacy  in adults.
All s
ubjects in Cohort 1 will continue to receive F/TAF plus their 
3rdARV agent and return for study visits through Week 48.
Cohorts 2, 3, an d 4
Cohorts 2, 3, and 4 will be enrolled b y cohort into two parts 
(Part s Aand B). Cohort 2 consists of 2 groups: Group 1 weighing 
≥25 kg and Group 2 
weighing 17kg to < [ADDRESS_1280564] be on a boosted protease 
inhibitor (PI ) as their 3rdARV agent and will switch their current 
2-NRTI -containing regimen to open -label F/TAF while continuing 
their boosted PI  [CONTACT_10782] 48 weeks. 
All subjects in Cohort 2, Group 2 andCohorts 3 and 4 will be on a 
boosted PI [INVESTIGATOR_911693] -specified 3rdagent sand will switch their 
current 2 -NRTI -containing regimen to open- label F/TAF while 
continuing their 3rdagents through 48 weeks. 
A minimum of 10 subjects who are on boosted -ATV as their 
3rdARV agent will be enrolled into Part A of eac h group of Cohort 2, 
as well as Cohorts 3 and 4. 
Cohorts 2, 3, and 4 will be enrolled as follows: 
Part A
Cohort Age RangeWeight 
RangeNumber of Subjects
ATV + 
F/TAFLPV or 
DRV 
+F/TAFOther 3rd
ARV Agents 
+ F/TAF
2, Group 1 6to<12years ≥ 25 kg n ≥ 10 n ≥ 6 n/a
2, Group 2 
(subjects able
toswallow a 
tablet)2 to < 12 years17 kg to 
< 25 kg n ≥ 10 n ≥ 7
3b(subjects 
unable to 
swallow a
tablet)2 to < 6 years TBD n ≥ 10 n ≥ 7
4a,b 1 month to 
< 2yearsTBD n ≥ 10 n ≥ 7
a DRV is not approved for Cohort 4
b Formulation, dosing, and population specific details for Cohorts 3 and 4 will be added 
via a protocol amendment after data is obtained from Cohort 2.
All subjects in Part A will undergo an IPK evaluation at either the 
Week 2 or Week 4 visit (+7 da ys) to confirm the dose of TAF.
F/TAF
Protocol GS -US-311-[ADDRESS_1280565] 2017Part B
Screening will be initiated for Part B following confirmation of TAF 
dose in Part A for each group of Cohort 2 and Cohorts 3 and 4. 
Approximately  10 additional total subjects will be enrolled in Part B 
and will receive F/TAF while continuing their 3rdARV agent
through 48 weeks.
Number of Subjects 
Planned:A minimum of 100 subjects will be enrolled. 
Target Population: HIV
-[ADDRESS_1280566] been virologically  
suppressed for ≥ 6consecutive months prior to screening on a stable 
2-NRTI -containing regimen .
Duration of 
Treatment:Subjects will receive study  treatment for at least 48 weeks. 
After completion of 48
weeks of trea tment in the study , all eligible
subjects will be given the option to participate in an extension phase 
of the study in which visits will occur every  12 weeks. [COMPANY_009] will 
provide 
F/TAF until: 
a)the subject turns 18 y ears old and F/TAF is commerciall y available 
for use in adults in the country  in which the subject is enrolled, or
b)F/TAF becomes commercially  available for pediatric use in the 
country  in which the subject is enrolled, or 
c)[COMPANY_009] Sciences elects to terminate development of F/TAF in the 
applicable country .
Diagnosis and Main 
Eligibility  Criteria:HIV-1 infected pediatric patients at Baseline /Day  1. 
Currently  on a stable 2- NRTI - containing regimen that includes a 
3rdARV agent for ≥ 6 consecutive months prior to screening.
Body weight and age at screening for all cohorts is as follows:
Cohort Age Range Weight
1 12 years to < 18 y ears ≥ 35 kg
2 (Group 1) 6 years to < 12 y ears ≥ 25 kg
2 (Group 2) (subjects able to 
swallow a tablet)2 years to < 12 y ears 17 kg to < 25 kg
3(subjects unable toswallow atablet) 2 years to < 6 y ears TBDa
4 1 month to < 2 y ears TBDb
a Body weight cutoff at screening to be determined based upon analysis of short -term
safety and PK data from Cohort 2 Part A before initiating Cohort 3 Part A
b Body weight cutoff at screening to be determined based upon analysis of short -term
safety and PK data from Cohort 2 Part A & Cohort 3 Part A
F/TAF
Protocol GS -US-311-[ADDRESS_1280567] 2017No documented or suspected resistance to TFV or FTC , including, 
but not limited to, the presence of reverse trans criptase mutations 
K65R, K70E, M184V/I, or 3 or more th ymidine analog -associated 
mutations (TAMs) that include M41L or L210W (TAMs are M41L, 
D67N, K70R, L 210W, T215Y/F, K219Q/E/N/R).
No laboratory  evidence of current active HBV or HCV infection.
Plasma HIV -1 RNA levels < 50 copi[INVESTIGATOR_014]/mL  for ≥ 6 consecutive 
months
.
Estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2by 
(Schwartz) formula .
Study  Procedures/
Frequency :At the Screening, Baseline/Day  1, and all subsequent study  visits,
laboratory  anal yses (hematology , chemistry , and urinaly sis), 
HIV-1 RNA, CD4+ cell count, complete or s ymptom directed 
physical examinations, and eGFR using the Schwartz formula will be 
performed. Serum (screening) or urine (all other visits) pregnancy  
tests wi ll be performed on female subjects of childbearing potential.
At screening ,HBV and HCV serolog ywill be analy zed.
Subjects will return for study  visits at Weeks 1, 2, 4, 8, 12, 24, 36,
and 48. After completion of 48weeks of treatment in the study , all 
eligible subjects will be given the option to participate in an 
extension phase of the study in w
hich visits will occur every  
12weeks.
Adverse events and concomitant medications will be assessed at each 
visit.
Serum will be collected for bone safety  tests (collected fasted) :
Cohort 1 only: Baseline/Day  1, Weeks 4, 12, 24, and 48and 
every  24weeks thereafter .
Cohort
s 2, 3, and 4: Baseline/Day  1, Weeks 8, 12, 24, 48, and 
every  24weeks thereafter
For all Cohorts, u
rine will be collected for urine chemistry  and 
selected renal safet y tests,including r etinol binding protein and 
beta-
2-microglobulin ,at Baseline/Day  1, Weeks 2, 4, 8, 12, 24, 48,
and every  12weeks thereafter.
For Cohorts 1 and 2 (all groups), metabolic assessments will be 
collected for f asting glucose and lipid panel (total cholesterol, HDL, 
direct LDL, and trigl ycerides) at Baseline/Day  1, Week s 24, 48, and 
every  24weeks (±10 days) thereafter. The fasting requirement for 
Cohorts 3 and 4 will be specif ied in a future protocol amendment.
F/TAF
Protocol GS -US-311-[ADDRESS_1280568] 2017Tanner stage assessment ( Appendix 7) will be performed for subjects 
≥
6years of age at the time of the visit at Baseline/Day 1, 
Weeks 24, 48, and every  12 weeks thereafter ,or until subjects reach 
Tanner Stage 5, after which point Tanner assessments will no longer 
be performed.
For all Cohorts, dual energy  x-ray absorptiometry (DXA) scans of 
the lumbar spi[INVESTIGATOR_911694]/Day  1, 
Weeks 24, 48, a nd every  24weeks thereafter to measure spi[INVESTIGATOR_727385]  (BMD) and total body  BMD.
PK sampling :
Single PK samples will be collected at the following visits for all 
cohorts :
Weeks 1 and 24: a single random PK sample.
Weeks 4 and 12: a single obser ved dosing PK sample at any  time 
between [ADDRESS_1280569] dose. (Note: Single observed 
dosing PK sample does not need to be collected at Week 4 if 
Intensive PK is also collected at the Week 4 visit)
Week 8: a trough sample at 0 hours (pre -dose, ≤ 30 minutes prior 
to dosing) at Week 8.
Intensive PK sampling :
Cohort 1 will participate in an I ntensive PK (IPK) evaluation at 
the Week 2visit as detailed in the PK manual .
Cohort 2 Part A will participate in an IPKevaluation during
either the Week 2 or Week 4 visit or within 7 days after the 
completion of Week 2 or Week 4 visit as detailed in the PK 
manual. The IPK collection schedule and fasting requirement for 
Cohorts 3 and 4 will be specified in a future protocol amendment.
PBMC collection :
PBMC coll ection will be performed at study sites that can 
perform PBMC processing. 
Cohorts 1 and 2 : PBMC collection will be performed at the 
Week 8 visit . 
Cohort 3, and 4: PBMC collection schedule will be specified in a
future protocol amendment.
F/TAF
Protocol GS -US-311-[ADDRESS_1280570] 2017Palatability  and Acceptability  Assessment :
Cohort 1: At the Week 2 visit, palatability  and acceptability  will 
be assessed 30 - 60 minutes after stud y drug dosing for all 
subjects undergoing IPK sampling. Acceptability  will also be 
assessed 30 - 60minutes after study  drug dosing for active 
subjects at the next study  visit immediately  following approval of 
this protocol at the site.
Cohort 2 Part A: Palatability  and acceptabilit y will be assessed at 
the Week 2 or Week 4 visit, or within 7 day
s after the completion 
of the Week 2 or Week 4 visit, 30 - 60 minutes after study  drug 
dosing for all subjects undergoing IPK sampling.
Cohorts 3 and 4 Part A: Palatability  and acceptability  will be 
assessed for subjects undergoing IPK sampling. Assessment 
schedule will be specified in afuture protocol amendment.
Subjects who prematurely discontinue from the study  or do not 
participate in the extension phase will be required to return to the 
clinic for a [ADDRESS_1280571] , Dose, and 
Mode of 
Administration:F/TAF tablets administered orall y QD in combination with a 
3rdARV agent ,with or without food (as determined by  [CONTACT_941] 3rdARV 
agent), dosed as follows:
Cohort Age andbody weight F/TAF dose (mg) with 3rdagent
1 12 to <18 y ears, ≥35k g200/25 for unboosted 3rdagent
200/10 for boosted 3rdagent
2, Group 1 6 to < 12 years, ≥25 k g 200/25
2, Group 2
(subjects able to 
swallow a tablet)2to < 12 years,
≥ 17 to <25kg120/15 
3(subjects unable 
to swallow a 
tablet)2 to < 6 years, TBD TBDa
4 1 month to < 2 years, TBD TBDa
a Dose, formulation, and population specific details will be specified by [CONTACT_911717], efficacy, and PK data from Cohorts 1 and 2 are 
available to guide dose and formulation selection of F/TAF to be administered in 
Cohorts 3 and 4.
F/TAF
Protocol GS -US-311-[ADDRESS_1280572] 2017Criteria forEvaluation:
Safety : Adverse events and clinical laboratory  tests, including selected renal
and bone safet y tests andBMD (assessed by  [CONTACT_11324] )
Efficacy : The efficacy  endpoints are:
The percentage of subjects with HI V
-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at 
Weeks 24and48 as defined by  [CONTACT_911718] -defined snapshot 
algorithm 
The change from baseline in CD4+ cell count (cells/μL ) and 
CD4+ percentage at Weeks 24 and48
Pharmacokinetics: The following plasma PK parameters will be calculated for TAF, 
TFV and FTC ( asapplicable): AUC tau, AUC last, Ctau, Cmax, Clast, Tmax, 
Tlast, λz, apparent CL, apparent V z, and T ½.
 
Statistical Methods: Plasma concentration and parameters of TAF, TFV, a nd FTC will be 
summarized using descriptive statistics by  [CONTACT_9084] ,dose level and 
type of boosted PI (eg, ATV/r or other PIs/r) if applicable. The 
AUC tauof TAF obtained in subjects from Cohort 1 or Part A of 
Cohort 2 G roups 1and2, Cohort 3, and Cohort 4, respectivel y,will 
be compared to historical adult data (ie,Study  GS-US-
311-1089). 
The comparisons will be conducted within each cohort and by  [CONTACT_5264] (ie. 200/25 mg vs 200/10 mg) , when applicable .TAF dose 
confirmation will be established if the 
lowe r bound of the 
90% confidence interval (CI) of the geometric mean ratio (pediatric 
subjects vs adult subjects) is above 70% for TAF AUC tau. The 
95% CIof the geometric mean estimates of Cl/F and V z/F will also 
be constructed for TAF. 
For efficacy  and safet y endpoints, results from each 
group or cohort
will be descriptive in nature. F/TAF results from each cohort will 
also be combined to describe the overall efficacy  and safet y profile 
of F/TAF in pediatric subjects. 
The percentage of subjects w ith HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at 
Weeks 24 and48 as defined by  [CONTACT_55257] -defined snapshot 
algorithm will be summarized by [CONTACT_911719] . The 95% CIfor 
the point estimate for F/TAF will be constructed. 
CCI
F!TAF 
Protocol GS-US-311-1269 
[COMPANY_009] Sciences , Inc. 
CONFIDENTIAL Final 
Amendme nt2 
The change from b aseline in CD4+ cell count and CD 4+ percentage 
will be summ arized by [CONTACT_765], group, and coho1 i us ing descriptive 
statistics. 
Bone and renal safety test data will be summari zed by [CONTACT_765], group, 
and coho1i. The incidences of treatment-emer gent ad verse events and 
treatment-emer gent laborato 1 y abno1malities will be summ arized by 
[CONTACT_19313], coho1i, and overall. 
Cohort 1: Twenty-five subjects in Coho1 i [ADDRESS_1280573] 
90% powe r to target a 95% confidence interval within 60% and 
140% of the geometric mean estimate of apparent CL and appar ent 
V2 ofTAF , respectively, assumin g a standard deviation of 0.60 for 
CL and 0.58 for V2 (natural log scale) estimated from 
Study GS-US-292-0106 Cohort 1 Pait A. 
Cohort 2 (Group 1) Part A: At least 10 subjects on b ooste d 
ATV+ F/TAF and 6 subj ects on boosted LPV or DRV + F/ TAF , 
compared with the population PK data from 44 adult subj ects on 
boos ted ATV+ F/TAF and 87 adult subjects on boosted LPV or 
DRV + F/ TAF in Study GS-US-311-[ADDRESS_1280574] 80% p ower to show the lower bound of a 90% CI of 
geometric me an ratio (pediatric su bjects vs. adult subj ects) greater 
than 70% for AUC1au of TAF, assumin g that the expected geometric 
mean ratios ofTAF AUC1au betwee n pediatric subj ects and adult 
subjects are e qual to 1 and the standai· d deviations are 0.40 
(with boosted ATV + F/TAF) and 0.33 (with booste d LPV or 
DRV + F/ TAF) ng*hr/mL for TAF AUCiau (natural log scale) 
estimated from the population PK data in Study GS-US-311-1089. 
Cohort s 2 (Group 2), 3, and 4, Part A: At least 10 su bjects on 
boos ted ATV+F/TAF and at l east [ADDRESS_1280575] agent+ F/T AF in each group or cohort, compai· ed with the 
population PK data from [ADDRESS_1280576] agent + F/T AF 
in Study GS-US-311-1089, will provide 90% power to show the 
lower bound of a 90% CI of geometric mean ratio (pediatric subjects 
vs. adult subjects) greater than 70% for AU Ciau ofTAF, assumin g 
that the expec ted geometric me an ratio ofTAF AUCtau betwee n 
pediatric su bjects and adult subjects is e qual to [ADDRESS_1280577] 
deviation is 0 .48 ng*hr/mL for TAF AUCiau (natural log scale) 
estimated from the population PK data in Study GS-US-311-[ADDRESS_1280578] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280579] 100 subjects receiving F/TAF from Cohort 1, 
Parts A and B of Cohort 2(Groups 1 and 2), Cohort 3, and Cohort 4 
combined will provide reasonable assess ment of safet y through 
Week 48inpediatric subjects.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280580] 2017GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
°C degrees Celsius
° F degrees Fahrenheit
AE adverse event
AIDS Acquired Immune Deficiency Syndrome
AK adenylate kinase
ALT alanine aminotransferase
ARV Antiretroviral
AST aspartate aminotransferase
ATV/r ritonavir boosted atazanavir 
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration versus time 
curve
AUC tau area under the concentration verses time curve over the dosing interval
BsAP Bone specific alkaline phosphatase
BMD bone mineral density
BUN blood urea nitrogen
CBC complete blood count
Clast the last observed quantifiable plasma concentration of drug
CL/F the apparent oral clearance after administration of the drug: 
CL/F Dose/AUC inf
where “Dose” is the dose of the drug
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CNS central nervous system
COBI, /co cobicistat 
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization 
CSR Clinical Study Report
CTX type 1 collagen crosslinked C -telopeptide
DXA Dual -energy X -ray absorptiometry
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DRV/r ritonavir boosted darunavir
DSPH Drug Safety and Public Health
DTG Dolutegravir
D2000006 [COMPANY_009] pre- clinical study: “A cardiovascular profile study follow ing a single oral 
administration of GS -7340 in the unrestrained conscious beagle dog”
ECG Electroc ardiogram
EDC electronic data capture
F/TAF
Protocol GS -US-311-[ADDRESS_1280581] 2017eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
EFV Efavirenz
EVG elvitegravir 
E/C/F/TAF elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/ emtricitabine (FTC) 
200mg/tenofovir alafenamide (TAF) 1 0mgsingle tablet regimen
ESDD Early Study Drug Discontinuation
FAS full analysis set
FDA ([LOCATION_002]) Food and Drug Administration
FDC Fixed -Dose Combination
FTC Emtricitabine
F/TAF emtricitabine/tenofovir alafenamide
GCP Good Clinical Practice (Guidelines)
GSI [COMPANY_009] Sciences, Inc.
GS-7340 tenofovir alafenamide, TAF, L-Alanine, N -[(S)-[[(1R) -2-(6-amino -9H-purin -9-yl)-1-
methylethoxy]methyl]/ phenoxyphosphinyl] -, 1-methylethyl ester
HAART highly active antiretroviral ther apy
HBsAg hepatitis B virus surface antigen serology
HBV hepatitis B virus
HCV hepatitis C virus
HCVAb hepatitis C virus serology
HDPE high-density polyethylene
HIV human immunodeficiency virus
HLGT high-level group t erm
HLT high-level t erm
HSP Hysterosalpi[INVESTIGATOR_662139]’s brochure
ICF Informed Consent Form
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IEC Indpendent Ethics Committee
IND Investigational New Drug (Application)
INSTI integrase strand transfer inhibitor
IMP Investigational Medicinal Product
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
KS Kaposi’s sarcoma
LLN lower limit of the normal range
LLOQ lower limit of quantification
F/TAF
Protocol GS -US-311-[ADDRESS_1280582] 2017LLT low-level t erm
LPV/r ritonavir boosted lopi[INVESTIGATOR_911695]-nucleoside reverse transcriptase inhibitor
NtRTI nucleotide reverse transcriptase inhibitor
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
NVP Nevirapi[INVESTIGATOR_050]
P1NP procollagen Type 1 N -terminal propeptide
PBMC peripheral blood mononuclear cell
PC-120-2005 [COMPANY_009] pre -clinical study: “Effect of GS -7340 -03 on Cloned hERG Potassium Channels 
Expressed in Human Embryonic Kidney Cells”
PI [INVESTIGATOR_911696] 
R990186 [COMPANY_009] pre- clinical study: “A pharmacologic assessment of the effect of GS -7340- 02 on 
therenal system of the rat”
R990187 [COMPANY_009] pre
-clinical study: “ A pharmacologic assessment of the effect of GS -7340 -02 on 
the gastrointestinal motility in the rat ”
R990188 [COMPANY_009] pre- clinical study: “ A pharmacologic assessment of the effect of GS -7340- 02 on 
the central nervous system of the rat ”
RAL Raltegravir
RBC Red blood cells
RNA ribonucleic acid
RPV Rilpi[INVESTIGATOR_911697]®, EVG/COBI/FTC/TDF (E/C/F/TDF) STR
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide (GS -7340)
TAFfumarate tenofovir alafenamide 
fumarate (GS-7340- 03)
TAM thymidine analog -associated mutations
TBD to be determined
TDF tenofovir disoproxil fumarate
TFV Tenofovir
TFV -DP tenofovir diphosphate (TFVpp)
Tmax the time (observed time point) of Cmax
F/TAF
Protocol GS -US-311-[ADDRESS_1280583] upper limit of the normal range
US [LOCATION_002]
Vz/F apparent volume of distribution during the terminal phase
z terminal elimination rate constant, estimated by [CONTACT_846011], plasma concentration of drug versus time curve
F/TAF
Protocol GS -US-311-[ADDRESS_1280584] [ZIP_CODE]. INTRODUCTION
1.1. Background
Human immunodeficiency virus -1 (HIV -1) infection is a life -threateni ng and serious disease that 
is of major public health interest around the world. There are approximately  2.1million people in 
North America and Western and Central Europe living with HIV -1 and 36.7 million people 
worldwide {Joint United Nations Programme on HIV/AIDS (UNAIDS) 2016 }, including 
2.1million children under 15 years of age {Joint United Nations Programme on HIV/AIDS 
(UNAIDS) 2016 }. This figure is likel y to underestimate the HIV disease burden in the pediatric 
population using the European Medicines Agency (EMA) categorization of adolescence as from 
12 to 16 or 18 years, depending on the region (EMA, Note for Guidance CPMP/I CH/2711/99).
The infection, if left untreated or suboptimall y treated, is characterized by [CONTACT_580877], ultimately
 resulting in death. Therapeutic strategies for the treatment of HIV -1 
disease hav e been significantly  advanced by  [CONTACT_727409] y (HAART); the introduction of HAART was associated with a dramatic decrease in 
acquired immune deficiency  syndrome (AIDS) -related morbidity and mortality  {Mocroft 1998, 
Palella 1998 , Sterne 2005 }.
Disease Pathophysiology
The pathogenesis of HIV -1 infection and the general virologic and immunologic principles 
underly ing the use of ARV therap y are similar between HIV -1 infected adult and pediatric 
patients. However, there are some important and unique issues for HIV -1 infected infants, 
children, and adolescents, including the following {Panel on Antiretroviral Therap y and Medical 
Management of HIV -infected Children 2011
}:
Acquisition of infection through perinatal exposure for man y infected children
In utero, intrapartum, and/or postpartum neonatal exposure to zidovudine and other ARV
medications in most perinatally  infected children
Age-specific differences in CD4+ cell counts and percentages
Changes in pharmacokinetic parameters with age caused b y the continuing development and 
maturation of organ systems involved in drug metabolism and clearance
Differences in the clinical and virologic manifestations of perinatal HIV -1 infection secondary  
to the occurrence of primary  infection in growing, immunologically  immature persons
Special considerations as sociated with adherence to ARV treatment for infants, children, and 
adolescents
Need for longer duration of therap y, with potentially  greater implications than in adults for 
long-term toxicity  and development of resistance
Differences in ph ysiological deve lopment of certain body  systems, including the skeletal 
system, where peak bone mass is not achieved until early  adulthood
F/TAF
Protocol GS -US-311-[ADDRESS_1280585] the adverse event profile 
of drugs, and that developmental changes associated with aging and growth are often not linear 
{Ginsberg 2004, McCarver 2004}.
Treatment
The goal of ARV therap y for HIV -1 infection is to delay  disease progression, improve immune 
function, and increase the duration of survival b y achieving maximal and prolonged suppression 
of HIV -1 replication. The av ailability  of highl y active antiretroviral therap y (HAART) 
combinations for the treatment of HIV
-1 infection has resulted in a dramatic reduction in 
Acquired Immunodeficiency  Syndrome (AIDS) related morbidity and mortality in the US and 
Europe {Mocroft 1998, Palella 1998 , Sterne 2005}. However, eradication of the virus is not 
possible with therapi[INVESTIGATOR_727370]. These therapi[INVESTIGATOR_911698], metabolic abnormalities, hematologic toxicities, and 
allergic reactions.
The 2017 Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection generall y 
recommend the use of 2 nucleoside/nucleotide reverse transcriptase inhibitor s (NRTIs )in 
combination with a 3rdagent (a non- nucleoside reverse transcriptase inhibitor [NNRTI ],a 
boosted protease inhibitor [PI]or an integrase strand transfer inhibitor [ INSTI ]) for treatment of 
children and adolescents with HIV infection. The choice of a regimen, including the 3rdagent, is 
individualized based on a number of factors inclu ding characteristics of the proposed regimen, 
patient characteristics and results of resistance testing {HHS Panel on Antiretroviral Therap y and 
Medical Management of HIV -
Infected Children with HI V 2017, Welch 2009 }.
Tenofovir (TFV) is a nucleotide analog that inhibits HIV -1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, is a preferred NtRTI for initial therapy , 
nephrotoxicity  is an identified risk, and reductions in bone mineral density  (BMD) have been 
shown that are larger than those seen with other NRTIs. Tenofov
ir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular levels 
of the active phosphory lated metabolite tenofovir diphosphate (TFV -DP), and approximately  90% 
lower circulating levels of TFV r elative to TDF at the clinical doses. The distinct metabolism of 
TAF offers the potential for an improved clinical profile compared with TDF. TAF is 
coformulated with the integrase strand transfer inhibitor elvitegravir (EVG), cobicistat (COBI), 
and emtric itabine (FTC) as Genvoy a®(elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
[E/C/F/TAF ])and with FTC as Descovy®(emtricitabine/tenofovir alafenamide [F/TAF]) . The
fixed -dose combination (FDC )Genvoy a®has been approved by  [CONTACT_911720] -naive individuals aged ≥ 12 y ears with estimated creatinine 
clearance ≥30 mL/min. The FDC Descovy®has also been approved in combination with other 
antiretroviral agents for the treatment of HIV -[ADDRESS_1280586] 35 kg .
Development of F/TAF increases the options available for the construction of ARV regimens for 
HIV-1 infected pediatric patients, and simplifies dosing of the NRTI /NtRTI backbone. The small 
F/TAF tablet size due to the low predicted mg dose of TAF in combination with FTC should 
improve acceptability  for children who can swallow tablets.
F/TAF
Protocol GS -US-311-[ADDRESS_1280587] [ZIP_CODE].2. Tenofovir Alafenamide (TAF, GS -7340)
1.2.1. General Information
Tenofovir alafenamide (GS- 7340, TAF, or L- Alanine, N -[(S)-[[(1R) -2-(6-amino -9H- purin-9- yl)-
1-methy lethoxy ]methy l]/phenoxy phosphiny l]- , 1-methy lethy l ester) is a second generation oral 
prodrug of TFV, a nucleotide analog that inhibits HIV
-1 reverse transcription. Tenofovir is 
metabolized intrace llularly  to the active metabolite, TFV -DP, a competitive inhibitor of HIV -1 
reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. 
Theintracellular metabolism of TAF and TFV are consistent with the 600- fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV.
TAF has been evaluated in a broad range of patients (e.g. treatment -naïve, virologically  
suppressed, etc) as part of Genvoy a®(E/C/F/TAF), Descovy®(F/TAF), or Odefsey®
(rilpi[INVESTIGATOR_12979]/emtricitabine/tenofovir alaf enamide [F/R/TAF ]). Specifically , Study GS-US-292-0106 
evaluated E/C/F/TAF (adult dose) in treatment -naïve adolescents. Theconclusions for Cohort 1 
(ART- naive adolescents treated with E/C/F/TAF) in this study  are as follows:
High virologic success was ach ieved (as assessed using the FDA -defined snapshot algorithm 
with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL) in ART- naive adolescents (90.0% and 92.0% virologic 
success at Weeks 24 and 48, respectively ), demonstrating efficacy  of the E/C/F/TAF FDC in 
this age group. These r esults are in accordance with pharmacokinetic ( PK)data (presented in 
an earlier CSR) that confirmed the E/C/F/TAF 150/150/200/10 mg doses for each component.
There was evidence of a robust immunological response to E/C/F/TAF in ART -naive 
adolescents. The mean (SD) increase from baseline in CD4 cell count was 
191(175.2) cells/μL  at Week 24 and 224 (170.3) cells/μL  at Week 48. The mean (SD) 
increase from baseline in CD4% was 7.7% (4.77%) at Week 24 and 9.3% (5.19%) at 
Week 48.
E/C/F/TAF was well tolerated, as evidenced by  [CONTACT_911721] y-drug-related 
SAEs and the absence of AEs leading to discontinuation of study  drug.
The lack of notable changes from baseline in height-age spi[INVESTIGATOR_911699] Z- scores at 
Weeks 24 and 48 indicates that subjects min eralized bone at rates consistent with those of the 
reference population. Few subjects experienced a clinically  relevant decrease from baseline 
in BMD.
Changes from baseline in serum creatinine and eGFR were consistent with the inhibitory  
effect of COBI on renal tubular secretion of creatinine, and are not considered reflective of 
changes in actual glomerular filtration. There were decreases from baseline in proteinuria, as 
assessed b y UPCR (urine protein to creatinine ratio).
E/C/F/TAF has been approved in adults and pediatric patients 12 y ears of age and older in 
the US and EU {[COMPANY_009] Sciences Inc 2016 , [COMPANY_009] Sciences International Limited 2016 }.
Pleas e refer to the respective I nvestigator’s Brochure for further information, including data from 
adult studies.
F/TAF
Protocol GS -US-311-[ADDRESS_1280588] [ZIP_CODE].2.2. Preclinical Pharmacology and Toxicology
[IP_ADDRESS]. Primary  Pharmacody namics
TAF, like TDF, is an orally bioavailable prodrug of TFV. Following oral administr ation, TAF is 
metabolized to TFV, a nucleotide analog (i.e., a nucleoside monophosphate analog) which is not 
dependent on an intracellular nucleoside kinase activity  for the first step in the conversion to the 
active metabolite, TFV -DP. The cellular enzy mes responsible for TFV metabolism to the active 
diphosphory lated form are 
aden ylate kinase (AK) { Robbins 1995} and nucleotide diphosphate 
kinase, which are highl y active and ubiquitous. AK exists as multiple isozy mes (AK1 to AK4), 
with the phosphory lation of TFV mediated most efficientl y by [CONTACT_184893]2.
The intracellular metabolism of TAF and TFV are consistent with the 600 -fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV. Metabolism of TAF was also studied in 
different human blood l ymphocyte subpopulations, CD4+ and CD8+ T -cells, NK cell s, B-cells 
and macrophages/monocy tes. TAF is metabolized inside host cells to the active metabolite 
TFV -DP. Concentration of the active metabolite TFV -DP was substantial in all cell populations.
[IP_ADDRESS]. Safety  Pharmacology
TAF monofumarate (GS -
7430- 02) has been ev aluated to determine potential effects on the 
central nervous s ystem ( Study  R990188), renal system ( Study  R990186), cardiovascular system 
(Study D2000006) and gastrointestinal sy stems ( Study  R990187). Single doses did not induce 
pharmacologic effects on th e central nervous s ystem of the rat (1000 mg/kg), the renal sy stem of 
the rat (1000 mg/kg), or the cardiovascular s ystem of the dog (100 mg/kg). TAF monofumarate 
(at 1000 mg/kg )
reduced distal transit and increased stomach weights starting 2 hours postdosi ng 
with reversibility  beginning by  6hours after dosing. The NOEL for gastrointestinal motility  was 
100mg/kg. The IC 50for the inhibitory  effect of TAF fumarate (GS -7340- 03) on hERG 
potassium current was estimated to be greater than 10 μM (Study  PC- 120 -2005).
1.2.3. Nonclinical Pharmacokinetics
Information regarding the TAF nonclinical PK is available in the current F/TAF IB.
1.2.4. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) or 
Fixed -Dose Combination (FDC) emtricitabine/tenofovir alafenamide 
(F/TAF)
Clinical trials entailing the use of TAF or F/TAF FDC are included in the F/TAF IB .
Drug Interaction Studies with TAF and 3rdARV Agents
TAF s ystemic exposure was found to be increased by  [CONTACT_911722] P-g lycoprotein inhibition. This 
led to the selection of TAF 10 mg in the E/C/F/TAF FDC tablet , which achieved TAF exposure 
bioequivalent to that achieved with TAF 25 mg (Study  GS-US-292- 0103), which is considered 
the reference exposure.
F/TAF
Protocol GS -US-311-[ADDRESS_1280589] 2017Three drug- drug interaction studie s (GS -US-311- 0101, GS -US- 120-0117, and GS -US-120-0118) 
have been conducted to determine the drug interaction potential of commonly  used 3rdagents 
with TAF . In combination, Studies GS -US-311- 0101, GS -US- 120-0117, and GS -US- 120-0118 
provide drug interaction data between TAF and boosted protease inhibitors (DRV/r, ATV/r, 
LPV/r), non -nucleoside reverse transcriptase inhibitors (EFV and RPV), and the integrase strand 
transfer (INST I) inhibitor dolutegravir (DTG) , and the effect of these 3rdagents on TAF 
exposu re is shown in Table 1-1. 
While no clinical drug
-drug interaction studies of TAF were conducted with RAL , MVC and 
NVP, no clinically relevant drug -drug interaction is expected based upon preclinical and clinical 
information.
Table 1-1. TAF AUC upon Co -administration of TAF (10 or 25 mg) with 
3rdAgent in Adults
Study Co-adm inistered 
3rdagentTAF dose evaluated in the 
DDI study (mg)Effect of 3rdagent on 
TAF AUC last
GS-US-120-0118ATV/r 10 ↑ 91%
LPV/r 10 ↑47%
DRV/r 10 ↑ 6%
DTG 10 ↑19%
GS-US-120-0117 RPV 25 ↓ 4%
GS-US-311-0101 EFV 40 ↓ 14%
Study  GS-US-311-1089 is an ongoing 48-w eek, randomized, double -blind ed, switch study  to 
evaluate F/TAF in HIV -1 infected, virologically  suppressed adults on regimens containing 
FTC/TDF. Safet y and efficacy of F/TAF 
200/10 or 200/ 25 mg in combination with the 
appropriate 3rdagent is being evaluated in addition to TAF and TFV PK.
1.3. Emtricitabine (FTC, Emtriva®)
Emtricitabine (5 -fluoro -1-[(2R, 5S) -2-(hydroxy methy l)-[1, 3] -oxathiolan - 5-yl] cytosine, FTC) is 
a
nNRTI that has demonstrated potent and selective inhibition of HI V. In HIV -infected adults,
FTC is administered as a 200 mg QD dose concurrently  with other ARV drugs. The 200 mg FTC
capsule formulation was approved b y the US Food and Drug Administration (FDA) for
marketing on 02 July  2003 and is available under the name [CONTACT_10881]®. In the European Union
(EU), marketing authorization was granted for both the 200 mg Emtriva®capsule formulation
and a 10 mg/mL  Emtriva®oral solution formulation on 24 October 2003, with indications for the
treatment of HIV infection concurrently  with other antiretroviral drugs in both adult and
pedia tric patients. Further information is available in the current Prescribing Information for 
Emtriva®.
F/TAF
Protocol GS -US-311-[ADDRESS_1280590] shifted
clinical attention towards ARV agents that optimize long -term safet y and tolerability. Young, 
newly  infected patients are diagnosed earlier, initiate therapy  earlier and look ahead towards 
lifelong therap y {Prejean 2011 }. Renal and bone health, in both of these contexts are 
increasingl y important 
{Capeau 2011}
Although more than [ADDRESS_1280591] limited treatment options for effective, safe and well 
tolerated once daily therapy. Adolescents with HIV infection are in need of ARV regimens for 
which therapeutic dosing has been validated b y pharmacokinetic data. Many  adolescents with 
HIV infection would benefit from the availability  of a simplified, fixed dose combination of 
F/TAF that combines potent efficacy , tolerability , a favorable toxicity  profile, and practical, 
convenient dosing.
[COMPANY_009] has developed the FDC produ ct F/TAF . Children ages 2to < 12 years old will benefit 
from the availability  of an NRTI /NtRTI backbone in a single formulation to be administered with 
other ARV agents. 
Switching from a 2
-NRTI -containing ARV regimen to a TAF -containing ARV regimen may  lead 
to improvement in renal and bone safet y parameters due to lower plasma TFV exposure. 
HIV-infected pediatric subjects may benefit from a fixed dose tablet or age appropriate 
formulation of F/TAF, which has the potential for an improved re nal and bone safet y profile 
relative to TDF, an important consideration for a population in which peak bone mass has not y et 
been achieved and for whom HIV treatment is anticipated to be life -long. 
1.5. Rationale for Dose Selection
The proposed F/TAF doses for this study  are expected to provide plasma exposures in the 
pediatric population that are comparable to those associated with safet y and efficacy  in adults. 
1.5.1. F/TAF Dose in Adolescents 12 to < 18 years of Age W eighing ≥35 kg
Therecommended F/TAF dose in adolescents 12 to < 18 yearsis200/10 mg or 200/25 mg based 
on the coadministered 3rdagent . Exposures of TAF, TAF -metabolite TFV ,and FTC observed 
following administration of F/TAF 200/10 mg or 200/25 mg in adolescents are consistent with 
exposures observed in adults.
For boosted regimens, such as LPV/r
, DRV/r and ATV/r, the recommended F/TAF dose is the 
adult strength tablet, 200/10 mg. For 
unboosted regimens, such as EFV, NVP, RAL  and DTG, 
the recommended F/TAF dose is the adult strength tablet, 200/25 mg. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280592] [ZIP_CODE].5.2. F/TAF Dose in Children 6 to < 12 Y ears of Age Weighing ≥25 kg and 
2to< 12 Years of Age Weighing 17 to < 25 kg
In the US, F/TAF 200/25 mg is approved for use in adults and adolescents (greater than 12 years 
of age and weighing ≥ 35 kg) when used with unboosted or boosted 3rdagents.
For children 6 to < 12 years old weighing ≥ 25 kg, t he proposed F/TAF dose for evaluation is
200/25 mg (Table 1-2).
For children 2 to < 12 years old weighing 17 to ˂25 kg, a reduced F/TAF dose of 120/1 5 mg is 
proposed for evaluation (Table 1-2).
Table 1-2. Pediatric F/TAF Dosing and Tablet Strength by [CONTACT_911723] (kg) Strength F/TAFa(mg)
≥25 to < 35 200/25b
≥17 to < 25 120/[ADDRESS_1280593] agent.
b This group will enroll only boosted PIs and this is the dose that will be used.
The dosing nomogram is structured to simplify  dosing and formulations and to avoid 
subtherapeutic dosing in a population requiring lifelong therapy  from a y oung age ,in which the 
implications of virologic failure may  be greater than in adults. The predicted exposures following 
administration of F/TAF 200/25 mg in children weighing ≥25 kg or F/TAF 120/ 15 mg in 
children weighing 17 to ˂ 25 kg are generall y within the range of those observed in adults and 
simulations of TAF and TFV (TAF -metabolite) exposures for these doses are shown in 
Figure 1-1and Figure 1-2below .
Rationale for TAF Doses in Children 6 to < 12 Y ears of Age Weighin g ≥25 kg and 
Children 2 to12 Y ears of Age Weighing 17 to < 25 kg
TAF and TFV exposures were predicted b y allometric scaling of adult exposures considering 
correlations between body weig ht and clearance (CL ) capacity .Model -predicted sy stemic 
exposures of TAF and TFV in children 6 to <12 years old and weighing 
≥ 25 kg administered 
F/TAF 200/25 mg or children 2 to < 12 years weighing 17 to < 25 kg with unboosted or boosted 
3rdagents are presented in Figure 1-1and Figure 1-2respectively . These simulations indicate 
similar predicted ranges of TAF and TFV exposure in children 6 to < 12 years weighing ≥ 25 kg 
and children 2 to < 12 years weighing 17 to < 25 kg following administration of F/TAF 
200/25 mg or 120/15 mg respectivel y with unboosted or boosted 3rdagents. Additionally , the 
range of expected TAF and TFV exposures are generall y within the range of those observed in 
the adult Phase 2/3 population, with TFV exposures that are generally  less than median TFV 
exposures (medi an AUC: 2360 h*ng/mL) observed in children 6 to < 12 y ears old with TDF 
(Study  GS-US-
104-0352).
F/TAF
Protocol GS -US-311-[ADDRESS_1280594] 2017Figure 1-1. Predicted TAF AUC in Children Fo llowing Administration of 
F/TAF 200/25 mg or 120/15 mga,b,c
a Theadult exposures for TAF were the population PK predicted exposures from GEN Phase 3 studies
(Genvoya NDA 207561, m5.3.3.5, Population PK Analysis of TAF and TFV following Administration of E/C/F/TAF STR)
b The observed AUC values for TAF in children ≥ 25 kg are from Study GS -
US-292-0106.
c For boosted agents, predicted exposures of TAF upon administration of TAF 25 mg with ATV/r are shown and are expected 
to encompass exposures of TAF upon coadministration with other boosted 3rdagents (LPV/r or DRV/r) ( Table1-1).
 
   
  
       
                                                                                       
  
 
  
  
 
   
      
 
           
     
 
                                                                                              
  
   
          
  
 
       
   
      
F/TAF
Protocol GS -US-311-[ADDRESS_1280595] 2017Figure 1-2. Predicted TFV AUC in Children Following Administration of 
F/TAF 200/25 mg or 120/15 mga,b,c
a The adult exposures for TFV were the population PK predicted exposures from GEN Phase 3 s tudies
(Genvoya NDA 207561, m5.3.3.5, Population PK Analysis of TAF and TFV following Administration of E/C/F/TAF STR)
b The observed AUC values for TFV in children ≥ 25 kg are from Study GS -
US-292-0106.
c For boosted agents, predicted exposures of TFV upon administration of TAF 25 mg with ATV/r are shown and are expected 
to encompass exposures of TFV upon coadministration with other boosted 3rdagents (LPV/r or DRV/r) ( Table 1-1).
Rationale for FTC Doses in Children 6 to < 12 Y ears of Age Weighing ≥ 25 kgand 
Children 2 to< 12 Y ears of Age Weighing 17 to < 25 kg
Emtricitabine is approved to be dosed at ≤6.1 mg/kg in children aseither a capsule or oral 
solution formulation {EMTRI VA®2012 }. Per the current Emtriva label, the approved dos e of 
200 mg FTC can be administered in adults with normal renal function and those with mild renal 
impairment (50 -80 mL /min), in whom FTC exposures were shown to be approximately  70% 
higher than adults with normal renal function {EMTRI VA®2012 }. In addition, a proposal for 
FTC/TDF low -dose tablets from the WHO Paediatric Antiretroviral Working Group 
{World Health Organization (WHO) 2011 }allows FTC doses up to 8.57 mg/kg (corresponding 
to a 40% increase over 6.1 mg/kg) for use in children. Given the approved doses for FTC and its 
dose-proportional pharmacokinetics, the proposed FTC dose sfor evaluation in children 
6to<
12years weighing ≥25 kg or 2 to < 6 years we ighing 17 to < 25 kg areexpected to result 
in exposures in the 
range of those providing a favo rable risk:benefit profile.
 
 
   
   
  
           
                                                     
 
 
   
     
                                                                                              
            
  
     
    
 
     
F/TAF
Protocol GS -US-311-[ADDRESS_1280596] 2017The F/ TAF FDC tablets for use in patients 6 to < 12 years weighing ≥25 kg or 2 to < 6 y ears 
weighing 17 to 
< 25 kg provide a range of FTC doses comparable to the approved doses which 
donot exceed 8.57 mg/kg .
1.5.3. Dosing in Cohorts 3 (2 to < 6 Y ears) and 4 (1 Month to < 2 Years)
The protocol will be amended to add dosing and formulation and specific inclusion/exclusion for 
Cohorts 3 and 4 once dose confirmation is established in C ohort 2.
1.6.
Risk/Benefit Assessment for the Study
All patients with HI V-1 infection should receive effective antiretroviral therap y. Potential risks 
associated with all classes of ARVs include immune re constitution sy ndrome, lipody strophy , and 
lactic acidosis with steatosis. The risk of class effects is considered to be low. I mportant 
identified risks will be appropriatel y managed b y study inclusion/exclusion criteria as well as 
through close clinical an d laboratory  monitoring during the stud y. Interim data will also be 
reviewed b y an independent data monitoring committee. Potential benefits may  include provision 
of a new antiretroviral therap y that is not currently available and which may have fewer side
effects than alternative therapi[INVESTIGATOR_014]. Other potential benefits include the knowledge that patient 
participation will contribute to the body  of knowledge of HIV therapi[INVESTIGATOR_014]. 
Potential toxicity  is appropriately  managed by  [CONTACT_110096]/exclusion criteria, cl ose clinical 
and laboratory monitoring, as well as specific toxicity  management guidance to investigators 
(refer to Section 7.5.1). 
The overall benefit
-risk assessment for F/TAF administered orally  once -daily  with food, in 
combination with boosted -PI[CONTACT_446931] 3rdARV agent , is favorable at this time.
1.7. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
F/TAF
Protocol GS -US-311-[ADDRESS_1280597] [ZIP_CODE]. OBJECTIVES
The primary objective sof this study  are:
To evaluate the PK of TAF and confirm the TAF dose in HIV
-1 infected children and 
adolescents virologicall y suppressed on 
a 2NRTI -containing regimen.
To evaluate the safet y and tolerability  ofF/TAF through Week 24.
The secondary  objectives of this study  are: 
To evaluate the PK of TFV and FTC .
To evaluate the safety, tolerability ,and efficacy of F/TAF through Week 48.
F!TAF 
Protocol GS-US-311 -1269 
[COMPANY_009] Sciences , Inc. 
3_ STUDY DESIGN 
3.1. Primary Endpoints 
The prima1y endpoints are: 
• The PK parameter AUCtau for TAF Final 
Amendment2 
• fucidence of treatment -emergent SAEs and all treatment-emergent adverse events throug h 
Week24 
3.1.1. Secondary Endpoints 
The secondaiy endpoints are: 
• PK parameters of Cmax, C1ast, Cl/F, and V2 IF for TAF , AUCtau, Cma.x, and Ctau for FTC and 
TFV 
• fucidence of treatment-eme rgent SAEs and all treatment-emergent adve rse events throug h 
Week48 
• The perce ntage of subjects with HIV-I RNA < 50 copi[INVESTIGATOR_014] /mL at Weeks 24 and 48 as defined 
by [CONTACT_55257] -defined snapshot algorithm 
• The change from baseline in CD4+ cell count (cells/µL) and CD4+ percentage at 
Weeks 24 and 48 
• The palatability and acceptab ility of the age-approp riate F/TAF fo1mul ation 
I 
I 
I 
3.2. Study Design 
This protocol describes an open-lab el, multi-coho1t switch study to evaluate the PK, safety, and 
efficacy of FIT AF in HIV- I infected children (1 month to < 12 yeai·s) and adolescents 
(12 to <18 yeai·s) who are vi rolog ically suppressed while on a stable 2-NRT I-containin g regimen. 
A minimum of 100 children and adolesce nt subjects, 1 month to < 18 years of age of either sex, 
will be emolled to receive F/TAF. The study will proceed in seque ntial coho rts as follows: 
CONFIDENTIAL Page [ADDRESS_1280598] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280599] [ZIP_CODE].2.1. Cohort 1 (Adolescents 12 to < 18 years, ≥ 35 kg )
All subjects in Cohort 1 (n = 25) willswitch their current 2-NRTI -containing regimen to 
open -label F/TAF while continuing on the ir3rdARV agent through 48 weeks.
Subjects will be enrolled to evaluate the stead y state P K and confirm the dose of TAF. 
An intensive PK (I PK) evaluation will be c onducted at the Week 2 visit to confirm the dose of 
TAF and to characterize TFV and FTC exposures as appropriate. Samples will be collected over 
24hours (pre and post dose )andwill be anal yzedonce they  are available from all subjects.
Replacement subjects may be enrolled if subjects do not complete all IPKprocedures or if IPK 
data is incomplete. Replacement subjects will not be enrolled in Cohort 1 for subjects who 
discontinue the study  due to treatment- related toxicity .
Following completion of the Week 2 IPK visit, all subjects will continue to receive F/TAF plus 
their 3rdARV agent and return for stud y visits through Week 48. 
3.2.2. Cohorts 2, 3, and [ADDRESS_1280600] be on a boosted protease inhibitor (PI) (Cohort 2 only ) or 
any other 3rdARV agent and 
will switch their current 2 -NRTI -containing regimen to open -label 
F/TAF while continuing their boosted PI  [INVESTIGATOR_1660] 3rdagent through 48weeks . A minimum of 
10subjects each 
in Groups 1 and 2 of Cohort 2, and Cohorts 3 and 4, who are on boosted -ATV
as their 3rdARV agent will be enrolled. Cohorts 2, 3, and 4 will be enrolled by  [CONTACT_911724] a 
two-part stud y (Part sA and B) as follows: 
Part A
A minimum of 67 subjects will be enrolled to evaluate the stead y state PK and confirm the dose 
of TAF with boosted ATV, L PV, DRV or other agents. 
Cohort # Age Range ATV + F/TAFLPV or DRV 
+ F/TAFOther 3rdARV Agents
+ F/TAF
2, Group 1a6 to < 12 years n ≥ 10 n ≥ 6 n/a
2, Group 2b2to <12 years n ≥ 10 n ≥ 7
3 2 to < 6 years n ≥ 10 n ≥ 7
4 1 month to < 2 years n ≥ 10 n ≥ 7c
a Cohort 2, Group [ADDRESS_1280601] weigh ≥ [ADDRESS_1280602] weigh 17 to < 25 kg at screening
c DRV is not approved for Cohort 4
All subjects in Cohort 2 Part A will undergo an IPK evaluation ateither theWeek 2 or Week 4 
visit or within 7 day s after the completion of theWeek 2 or Week 4 visit to confirm the dose of 
TAF and to characterize the exposure of TFV .
TAF dose confirmation will be established if the 
exposure is comparable to that associated with efficacy  in adults. Samples will be collected over 
8hours (pre and post dose) and will be anal yzedonce they  are available from all subjects. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280603] 2017Replacement subjects may be enrolled if subjects do not comple te all I PK procedures or if the 
IPK data is incomplete but will notbe enrolled for subjects who discontinue the study  due to 
treatment -related toxicity.
Following completion of the I PK, all subjects will continue to receive F/TAF plus their 
3rdARV agent and return for study  visits through Week 48.
The I PK collection schedule and fasting requirement for Cohorts 3 and 4 will be specified in a 
future protocol amendment.
Part B
After confirmation of TAF dose in Part A (IDMC review required) for each cohort ( and group
for Cohort 2), approximately  10additional total subjects will receive F/TAF while continuing
their 3rdARV agent through 48 weeks in Part B to evaluate the safet y, tolerability  and efficacy  of 
the treatment regimen.
3.2.3. Study Procedures and Frequency for All Subjects (All Cohorts and 
Parts Aand B)
At the Screening, Baseline/Day  1, and all subsequent study visits laboratory  analy ses 
(hematology , chemistry , and urinal ysis), HIV -1 RNA, CD4+ cell count, e GFR using the 
Schwar tz formula ,anda complete or symptom directed ph ysical examinations will be 
performed. Serum (screening) or urine (all other visits) pregnancy  tests will be performed on 
female subjects of childbearing potential.
At screening HBV and HCV serolog
y will be analy zed.
Subjects will return for study  visits at Weeks 1, 2, 4, 8, 12, 24, 36, and 48. After completion of 
48weeks of treatment in the study , all eligible subjects will be given the option to participate in 
an extension phase of the study in which visit s will occur every  12 weeks. Adverse events and 
concomitant medications will be assessed at each visit.
Tanner stage assessment will be performed at Baseline/Day 1, Weeks 24 and48,and every  
12weeks thereafter or until subjects reach Tanner Stage 5, after which point Tanner assessments 
will no longer be performed.
Dual energy  x-ray absorptiometry  (DXA ) scans of the lumbar spi[INVESTIGATOR_911700]/Day  1, Weeks 24 and48, and every  24 weeks thereafter to measure spi[INVESTIGATOR_911701] y (BMD) and total bod y BMD.
For all subjects ,
single PK samples will be collected: A single random PK sample will be 
collected at Weeks [ADDRESS_1280604] dose during Weeks 4 and 12(Note: For subjects in Cohort 2
Part A , asingle observed dosing PK sample does not nee d to be collected at Week 4 if I ntensive 
PK is also collected at the Week 4 visit). A trough sample will be collected at 0 hours (pre-dose, 
≤ 30 minutes prior to dosing) during Week 8.
F/TAF
Protocol GS -US-311-[ADDRESS_1280605] 2017PBMC collection will be performed at sites that ha ve PBMC processing capability . For subjects 
in Cohort s
1and 2 ,PBMC collection will be performed atthe Week 8 visit . PBMC collection 
schedule for 
Cohorts 3 and 4 will be addressed in a future protocol amendment. For PK profiling 
in PBMCs ,blood samples will be collected at 0 hours (≤ 30 minutes pre-dose). Details of PBMC 
collection and processing will be documented in the Pharmacokinetic Sample Coll ection, 
Processing, Storage, and Shipment Manual ( PK manual ).
Palatability and acceptability will be assessed in Cohort 1 subjects 30 - 60 minutes after stud y 
drug dosing for all subjects undergoing IPK sampling. For Cohort 1 subjects that are currentl y on 
study  and are bey ond the Week 2 visit, an acceptability  assessment is required once, preferably  
at the next clinic visit following the approval of this protocol amendment at the site. Palatability
and acceptability will be assessed 30 - 60minutes after study  drug dosing for all subjects 
undergoing I PK sampling in Part A of Cohorts 2, 3, and 4 . 
Serum will be collected for bone safety  tests (collected fasted), including bone specific alkaline 
phosphatase (
BsAP), serum phosphorous, procollagen ty pe 1-N-terminal propeptide (P1NP), 
C-type collagen sequence (CTX), parathy roid hormone (PTH), 1,25- OH vitamin D, and 25 -OH 
vitamin D (for Cohort 1: Baseline and Weeks 4, 12, 24, and 48 (±6days)and every  24 weeks 
thereafter ; for Cohorts 2,3, and 4: Base line and Weeks 8, 12, 24, and 48 (±6 days)and every  24 
weeks thereafter ).
For all cohorts and groups, urine will be collected for urine chemistry, and selected renal safet y 
tests, including retinol binding protein, and beta -2-microglobulin at Baseline/Day 1, 
Weeks 2, 4, 8, 12, 24, 48, and every  12 weeks thereafter. 
For Cohorts 1 and 2 (all groups), m
etabolic assessments will be collected for f asting glucose and 
lipid panel (total cholesterol, HDL, direct LDL, and trigl ycerides) at Baseline/Day 1, 
Weeks 24, 48, and every  24weeks (±10 days) thereafter .
Tanner stage assessment will be performed at Baseline/Day 1, Weeks 24and48, and every  
12weeks thereafter ,or until subjects reach Tanner Stage 5, after which point Tanner assessments 
will no longer be performed.
Dual energy  x
-ray absorptiometry  (DXA )scans of the lumbar spi[INVESTIGATOR_911700]/Day  1, Weeks 24 and48, and every  24weeks thereafter to measure spi[INVESTIGATOR_911701] y (BMD) and total bod y BMD.
Subjects who prematurely discontinue the stud y or do not participate in the extension phase ,as 
well as subjects who prematurely  discontinue prior to Week 48, will be required to return to the 
clinic 30 day s after the completion of the study  drug for a 30 Day  Follow up visit. 
F!TAF 
Protocol GS-US-31 1-1269 
[COMPANY_009] Sciences , Inc. Final 
Amendment2 
Subjects will receive their assigned tr·eatment for 48 weeks. After comp letion of 48 weeks, a ll 
subjects will be given the optio n to paiiicipate in an extension phase of the study. [COMPANY_009] will 
prov ide F/TAF until a) the s ubject turns 18 and F/TAF is comme rcially available for use in 
adults in the country in which the subject is em olled or, b) F/TAF becomes commercially 
available for pediatr · ic use in the country in which the s ubject is emolled or, c) [COMPANY_009] Sciences 
elects to tenninate developme nt of F/TAF in the applicable country. 
In the extension phase of the study , subjects will return for study visits eve1 y 12 weeks. During 
these visits , subjects will be assessed at vaiying intervals for AEs and concomita nt medications, 
Tanner Stage assessme nts, physical exams, vital signs, height measurement s, 12-lead ECGs, 
urine collection , blood sampling , eGFR, CD4+ cell count and perce ntage, plasma HIV-I RNA, 
DXA scans , and study dmg dispe nsation and accountability. Refer to Sectio n 6.[ADDRESS_1280606] Week 48 assessments. 
Figure 3-1. 
Screen ing 
$ 35 days prior 
to Day 1 
Screening Study Schema 
Baseline/ 
Dayl COHORT 1 
12 to< 18YR 
IPK 
(Wee k 2) 
PART A 
COHORT 2, 6 to < 12 YR 
GROUP 1, <! 25 kg 
COHORT 2, 2 to < 12 YR 
GROUP 2, 17 to< 25 kg Week48 30 Day 
Follow-Up 
Extens ion 
Phase 
30 Day 
Follow -Up 
-or-
Extension 
Phase 
$ 35 days prior Base line/ IPK Week48 
to Day 1 Day 1 (Week 2 or 4) 
Acceptable Week 4 
b 
PK & Safety Data a 
Screening PARTB 
COHORT 2, 6 to < 12 YR 
GROUP 1, <! 25 kg 
COHORT 2, 2 to < 12 YR 
GROUP 2, 17 to< 25 kg 
$ 35 days prior Basel ine/ 
to Day 1 Day 1 Week48 
a Patt B screening will initiate after analysis of intensive PK samp les and confumation ofTAF dose in corresponding age 
cohott in Patt A. 
b TI1e screening schema for Cohotts 3 and 4 will be specified in a future protocol amendment. 
3.3. Study Treatments 
In Coho 1 i 1, F /TAF will be admin istered orally , dosed once-daily in comb ination with the ir 
3rd ARV agent, at approx imately the saine time each day, either with or without food, as 
determ ined by [CONTACT_423] 's 3rd ARV agent. 
CONFIDENTIAL Page [ADDRESS_1280607] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280608] 2017In Cohort s 2,3, and 4, F/TAF will be administered orally , dosed once -daily  in combination with 
their3rdARV agent, at approximately  the same time each day , either with or without food, as 
determined b y the subject’s 3rdARV agent. The F/TAF dose will be based on the subject’s 
weight and 3rdARV agent.
On the morning of the IPKvisit,subjects in Cohort [ADDRESS_1280609] dose at the time of the visit.
3.4. Duration of Treatment
Subjects will receive their assigned treatment for 48 weeks. All subjects that complete 48weeks
of treatment will be given the option to 
participate in an extension phase of the study  where 
[COMPANY_009] will provide F/TAF until a) the subject turns 18 years old and F/TAF is commerciall y 
available for use in adults in the country  in which the subject is enrolled or b) F/TAF becomes 
commerciall y available for pediatric use in the country in which the subject is enrolled or 
c)[COMPANY_009] Sciences elects to terminate development of F/TAF in the applicable country .
3.5. Criteria for Discontinuation of Study Treatment
Study  medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investiga tor, affect assessments of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator.
Unacceptable toxicity or toxicity  that, in the judgment of the inve stigator, compromises the 
ability  to continue study -specific procedures or is considered to not be in the subject’s best 
interest .
Therapeutic failure (i.e., virologic failure as per Section 6.10).
Subject request to discontinue for an y reason .
Subject noncompliance .
F/TAF
Protocol GS -US-311-[ADDRESS_1280610] 2017Pregnancy  during the study ; refer to Appendix 5.
Discontinuation of the study  at the request of [COMPANY_009], a regulatory  agency  or an institutional 
review board or independent ethics committee (IRB/IEC)
.
F/TAF
Protocol GS -US-311-[ADDRESS_1280611] meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)HIV-1 infected male and female pediatric patients aged 1 month to < 18years at 
Baseline /Day  1(according to requirements of the enrolling cohort)
2)Subject able to give written assent prior to an y screening evaluations if they have the abilit y 
to read and write
3)Parent or guardian able to give written informed consent prior to an y screening evaluations 
and willing to compl y with study  requirements 
4)A negative serum β-HCG pregnancy  test is required for female subjects of childbearing 
potential only  (as defined in Appendix 5)
5)Body weight at screening as follows:
Age Range Weight
Cohort 1 12 years to < 18 years ≥ 35 kg
Cohort 2: Group 1 6 years to < 12 years ≥ 25 kg
Cohort 2: Group 2 (able to swallow  a tablet) 2years to < 12 years 17kg to < 25 kg
Cohort 3 (unable to swallow a tablet) 2 years to < 6 years TBDa
Cohort 4 1 month to < 2 years TBDb
a Body weight cutoff at screening to be determined based upon analysis of short -term safety and PK data from Cohort 2 
Part A before initiating Cohort 3 Part A
b Body weight cutoff at screening to be determined based upon analysis of short -term safety an d PK data from Cohort 2 
PartA& Cohort 3 Part A
6)Currently  on a stable 2- NRTI -containing regimen that includes a 3rdARV agent for 
≥ 6consecutive months prior to screening .
7)Plasma HI V-1 RNA levels < 50 copi[INVESTIGATOR_014]/mL for ≥ 6consecutive months preceding the 
screening visit (measured at least twice using the same assay )and not experienced 
twoconsecutive HIV -1 RNA above detectable levels after achieving a confirmed 
(twoconsecutive) HIV -[ADDRESS_1280612] y ear. 
a)To determine virologic suppression in the preceding 6 months prior to screening, the 
lower limit of quantification (LLOQ) b y the local HIV -1 RNA assay  may  be used, onl y if 
its LLOQ is great er than 50 copi[INVESTIGATOR_014]/mL  (e.g. LLOQ of 75 copi[INVESTIGATOR_014]/mL).
F/TAF
Protocol GS -US-311-[ADDRESS_1280613] [ZIP_CODE])Estimated glomerular filtration rate ( eGFR)  90mL/min/1.73m2by (Schwartz) formula
9) All male subjects and those female subjects of childbearing potential or those who reach 
childb earing potential during stud y participation (as defined in Appendix 5) must agree to 
utilize highly  effective contraception methods while on study  treatment or agree to abstain 
from heterosexual intercourse throughout the study period and for [ADDRESS_1280614] 
dose of study  drug; highly  effective methods normally  utilize two separate forms of 
contraception, one of which must be an effective barrier contraceptive method. Pre -pubertal 
females (Tanner stages 1 and 2) are not considered to be of childbearing potential, unless 
onset of menarche has occurred. See Appendix 5for definition of females of childbearing 
potential.
10)
Female subjects who utilize hormonal contraceptive as one of their birth control methods 
must have used the same method for at least three months prior to study  dosing. 
11)Adequate hematologic function defined as:
a)Absolute neutrophil count ≥500 cells/mm3(Subjects with neutrophil count of < 500/mm3
documented at least twice within 6 months of screening, and in who, according to the 
investigator, there is no evidence of immunosuppression associated with low neutrophil
count, can enroll in the study  contingent upon approval from the [COMPANY_009] study Medical 
Monitor.)
b)Hemoglobin > 8.5 g/dL
c)Platelets ≥50,000/mm3
12)Hepatic transaminases (AST and ALT) 5 × upper limit of normal (ULN)
13)For subjects on all 3rdARV 
agents except ATV ,total bilirubin ≤ 1.5 mg/dL or normal direct 
bilirubin
14)For subjects on ATV ,total bilirubin ≤ 3.0 mg/dL  or normal direct bilirubin
15)Normal ECG (or if abnormal, determined b y the investigator to be not clinically significant)
16)Must be willing and able to comply  with all study  requirements 
17)No opportunistic infection within 30 day s of study entry  (at Baseline /Day  1)
18)Subject is able to swallow a tablet
F/TAF
Protocol GS -US-311-[ADDRESS_1280615] [ZIP_CODE].3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study . 
1)An acquired immunodeficiency  syndrome (AIDS) -defining condition with onset within 
30days prior to screening 
2)Life expectancy  of < 2 years.
3)Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within 30 day s prior to Baseline/Day  1
4)Evidence of active pulmonary  or extra -pulmonary  tuberculosis disease within 3 months of 
the screenin g visit 
5)Anticipated requirement for rifam ycin treatment whi le participating in the study . 
Note: proph ylactic isoniazid therapy  for latent tuberculosis is allowed.
6) Active HCV infection defined as positive for HCV ant ibody  and having detectable 
HCV RNA .
a)Note: subjects with positive HCV antibod y and without detectable HCV RNA are 
permitted to enroll.
7)Positive hepatitis B surface antigen or other evidence of active HBV infection. 
a)Note: Subjects with positive HBV surface antibody and no evidence of active HBV
infection are permitted to enroll. 
8)Subjects with a historical genot ype that have documented or suspected resistance to TFV or 
FTC, including, but not limited to, the presence of reverse transcriptase mutations K65R, 
K70E, M184V/I, or 3 or more thy midine analog -associated mutations (TAMs) that include 
M41L  or L210W (TAMs are M41L, D67N, K70R, L 210W, T215Y/F, K219Q/E/N/R).
9)Have an y serious or active medical or ps ychiatric illness which, in the opi[INVESTIGATOR_684], would interfere with subject treatm ent, assessment, or compliance with the 
protocol. This would include uncontrolled renal, cardiac, hematological, hepatic, pulmonary  
(including chronic asthma or active tuberculosis), endocrine (e.g., diabetes), central nervous, 
gastrointestinal (including an ulcer), vascular, metabolic (thy roid disorders, adrenal disease), 
immunodeficiency  disorders, active infection, or malignancy  that are clinically  significant or 
requiring treatment (within 30 days prior to Baseline /Day  1).
10)
Subjects experiencing decompensated cirrhosis ( e.g., ascites, encephalopathy ).
F/TAF
Protocol GS -US-311-[ADDRESS_1280616] 201711)A history  or ongoing malignancy  other than cutaneous Kaposi’s sarcoma (KS), basal cell 
carcinoma, or resected, non -invasive cutaneous squamous carcinoma. Subjects with 
biopsy -confirmed cutaneous KS are elig ible, but must not have received any  systemic 
therap y for KS within 30 days of screening and are not anticipated to require s ystemic 
therap y during the stud y.
12)Pregnant or lactating subjects
13)Current alcohol or substance abuse judged b y the Investigator to potentiall y interfere with 
subject compliance.
14)Have history  of significant drug sensitivity  or drug allergy .
15)Known hy persensitivity  to the investigational medicinal product (IMP), the metabolites, or 
formulation excipi[INVESTIGATOR_841].
16)Have previously  participated in a n investigational trial involving administration of any  
investigational agent, other than TDF, within 30 day s prior to the study  dosing.
17)Participation in any  other clinical trial without prior approval from sponsor is prohibited 
while participating in this trial.
18)Subjects receiving ongoing therap y with an y of the following medications in the table below, 
including drugs not to be used with FTC, TAF or their 3rdARV agent (refer to the individual 
agents Prescribing Information) .
Table 4-1. Prohibited Medication while on Study
Medication Class Prohibited Medications
Anticonvulsants carbamazepi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_050], phenobarbital, phenytoin
Antimycobacterials rifapentine, rifabutin, rifampin
Antivirals cidofovir, ganciclovir, valganciclovir
Herbal/Natural SupplementsSt. John’s Wort, Echinacea, Milk thi stle (i.e., silymarin), 
Chinese herbsho-saiko -to (or Xiao -Shai-Hu-Tang)
Other probenecid
* Administration of any of the above prohibited medications must be discontinued at least 30 days prior to the Baseline/ Day 1 
visit andfor the duration of the study.
F/TAF
Protocol GS -US-311-[ADDRESS_1280617] is eligible for the study  prior
to enrollment.
Subjects will be assigned a screening number at th e time of consent. 
The enrollment and Baseline/Day [ADDRESS_1280618] number as signment and enrollment may  be performed up to 7 day s prior to the 
Baseline/Day [ADDRESS_1280619] 
eligibility  has been confirmed by [CONTACT_1034] .
All subjects will switch their current 2-NRTI -conta ining regimen to F/TAF while continuing 
their protocol -
specified 3rdARV agent.
IWRS will assign study  drug bottle numbers for dispensing stud y drug at study  visit s.Initiation 
of treatment with the study  drug must take place within 24 hours after the Baseline/Day 1 visit.
5.2. Description and Handling 
5.2.1. Formulation s
[IP_ADDRESS]. Emtricitabine /Tenofovir Alafenamide ( F/TAF )
[IP_ADDRESS].1. Emtricitabine 200 mg/Tenofovir Alafenamide 25 mg tablets
Emtricitabine 200 mg/Tenofovir Alafenamide 25 mg tablets are rectangular -shaped, film -coated 
blue tablets that are debossed with "GSI" on one side of the tablet and "225" on the other side of 
the tablet. The F/TAF tablet cores contain 200 mg of emtricitabine and 25 mg of tenofovir 
alafenamide. In addition to the active ingredients, the F/TAF tablets contain croscarmellose 
sodium, magnesium stearate, and microcry stalline cellulose. The tablet cores are film coated 
with FD&C Blue #2/ indigo carmine aluminum lake, poly ethylene gl ycol, poly vinyl alcohol, talc, 
and titanium dioxide.
F/TAF
Protocol GS -US-311-[ADDRESS_1280620] [ZIP_CODE].[IP_ADDRESS]. Emtricitab ine 200 mg/Tenofovir Alafenamide 10 mg tablets
Emtricitabine 200 mg/Tenofovir Alafenamide 10 mg tablets are rectangular -shaped, film -coated 
gray tablets that are debossed with "GSI" on one side of the tablet and "210" on the other side of 
the tablet. The F/TAF tablet cores contain 200 mg of emtricitabine and 10 mg of tenofovir 
alafenamide. In addition to the active ingredients, the F/TAF tablets contain croscarmellose 
sodium, magnesium stearate, and microcry stalline cellulose. The tablet cores are film coat ed 
with iron oxide black, poly ethylene gly col, poly vinyl alcohol, talc, and titanium dioxide.
[IP_ADDRESS].3. Emtricitabine 120mg/Tenofovir Alafenamide 1 5mg tablets
Emtricitabine 120mg/Tenofovir Alafenamide 1 5mg tablets are round ,plain faced, film-coated 
white table ts.Alternatively  F/TAF 120/15 mg tablets are round, debossed with “GSI”on one 
side of the tablet and “15” on the other side, film -coated white tablets. The F/TAF tablet cores 
contain 120 mg of emtricitabine and 15 mg of tenofovir alafenamide. In addition to the active 
ingredients, the F/TAF tablets contain croscarmellose sodium, magnesium stearate, and 
microcry stalline cellulose. The tablet cores are film coated with polyethylene gl ycol, poly vinyl 
alcohol, talc, an d titanium dioxide.
5.2.2. Packaging and Labeling
Emtricitabine/Tenofovir Alafenamide ( F/TAF ) tablets are packaged in a white high densit y 
polyethylene (HDPE) bottle. Each bottle contains 30 tablets, silica gel desiccant, and pol yester 
packing material. Each bottle is capped with a white, continuous thread, child- resistant, 
polypropylene screw cap fitted with an induction -sealed, aluminum
-faced liner.
Study  drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet a pplicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations. All labels for study  drug bottles to be distributed to 
centers in the US, EU and the rest of the countries will meet all applicable requirements of the 
US Food and Drug Administration (FDA) and Annex 13 of Good Manufacturing Practices: 
Manufacture of investigational medicinal products (February 2010) and/o r other local regulations 
as applicable .
5.2.3. Storage and Handling
Emtricitabine /Tenofovir Alafenamide (F/TAF )should be stored at a controlled room temperature 
of 25 °C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
Storage conditio ns are specified on the label. Until dispensed to the subjects, all bottles of study  
drugs should be stored in a securel y locked area, accessible onl y to authorized site personnel.
To ensure the stabilit y and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied . Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact [CONTACT_10850] . 
Appropriate precautions should be followed to avoid direct ey e contact [CONTACT_911725].
F/TAF
Protocol GS -US-311-[ADDRESS_1280621] [ZIP_CODE].3. Dosage and Administration
All subjects in Cohort 1 will switch their current 2 -NRTI -containing regimen toF/TAF while
continuing their3rdARV agent .
All subjects in Cohort s 2, 3, and 4 willswitch their current 
2-NRTI - c ontaining regimen to F/TAF and must be on a boosted -PI [INVESTIGATOR_911702] 
3rdARV agent as applicable per cohort .
5.3.1. Cohort 1 (12 years to < 18 years, ≥ 35 kg )
F/TAF fixed -dose combination tablets will be provided by  [CONTACT_911726] y, once daily as noted below in Table 5-1.The 3rdARV agent will be 
prescribed b y the Investigator and the subject will be responsible for obtaining the 3rdARV agent 
prior to Baseline/Day  [ADDRESS_1280622]’s 3rdARV agent for reasons other 
than virologic failure must discuss this change with the [COMPANY_009] Medical Monitor. Refer to 
Section 6.10 for more information.
Atthe IPKand at the single observed dosing PK sampling visits at Week s4 and 12, s ubjects will 
be administered their dose of study  medication and their 3rdARV agent in the clinic with food 
prior to the PK sampling.
Subjects will receive their assigned treatment for 48 weeks. After completion of 48weeks, all 
subjects will be given the option to participate in an extension phase of the study .[COMPANY_009] will 
provide 
F/TAF until a)The subject turns 18years old and F/TAF is commercially  available for 
use in adults in the country in which the subject is enrolled or b) ,F/TAF becomes commercially  
available for pediatric use in the country  in which the subject is enrolled or c), [COMPANY_009] Sciences 
elects to terminate development of F/TAF
in the applicable country . 
Table 5-1. Cohort 1 Dosing Recommendation for F/TA F in combination with 
3rdARV Agents
Cohort Age and body weight F/TAF dose (mg) with 3rdagent
1 12 to < 18 years, ≥ 35 kg200/25 for unboosted 3rdagent
200/10 for boosted 3rdagent
5.3.2. Cohort s 2, 3, and 4
F/TAF fixed -dose combination tablets will be provided by  [CONTACT_911726] y, once daily as noted above in Table 5-1. The subject’s 3rdARV agent will be 
prescribed b y the Investigator and the subject will be responsible for obtaining the 3rdARV agent 
prior to Baseline/Day  [ADDRESS_1280623] ingvisits , subjects will be administered their dose of stud y medication and their 
3rdARV agent in the clinic with food prior to the PK sampling.
F/TAF
Protocol GS -US-311-[ADDRESS_1280624] 2017Table 5-2. Cohort s 2, 3, and 4 Dosing Recommendations for F/T AF
Cohort Age and body weight F/TAF dose (mg) 
2, Group 1 6 to < 12 years, ≥ 25 kg 200/25
2, Group 2 (able to sw allow  a tablet) 2to <12 years, ≥ 17to < 25 kg 120/15 
3(unable to swallow a tablet) 2 to < 6 years, TBD TBDa
4 1 month to <2 years, TBD TBDa
a Dosage, using weight appropriate F/TAF dispersible tablets prepared as an oral suspension, will be specified by [CONTACT_911717], efficacy, and PK data from Cohorts 1 and 2 are available to guide dose selection of F/TAF 
to be administered in Cohorts 3 and 4. Subjects under 6 years of age who cannot swallow tablets will be allowed to choose 
this formulation for treatment as well.
5.4. Prior and Concomitant Medications
The use of medications for the treatment of HIV, other than thestudy  treatment (i.e., F/TAF ) and 
baseline 3rdARV agent ,is prohibited. Medications listed in Table 5-3and use of herbal/natural 
supplements are excluded or should be used with caution while subjects are participating in the 
study  due to potential drug -drug interactions with the study  drugs. 
Should subjects have a need to initiate treatment with any exclud ed or prohibited concomitant 
medication, the [COMPANY_009] Sciences
Medical M onitor must be consulted prior to initiation of the new 
medication. In instances where a prohibited medication is initiate d prior to discussion with the 
Sponsor, the Investigator must no tify [COMPANY_009] Sciences as soon as he/she is aware of the use of the 
prohibited medication.
Table 5-3. List of Prohibited Medications and Medications That AreTo Be Used 
With Caution
Medication Class Prohibited Medications Medications To Be Used With Caution
Antiarrhythmics amiodarone, quinidine: May increase 
concentration of TAF and/or TFV
Anticonvulsants carbazepi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_050], 
phenobarbital, pheynytoin
Antimycobacterials rifapentine, rifabutin, rifampin clarithromycin: may increase concentration of 
TAF and/or TFV
Antifungals itraconazole, ketoconazole, voriconazole: may 
increase concentration of TAF and/or TFV
Antivirals cidofovir, ganciclovir, valganciclovir acyclovir, valacyclovir
Calcium channel 
blockersdiltiazem, felodipi[INVESTIGATOR_050], verapamil: may increase 
concentration of TAF and/or TFV
Digoxin Concomitant use may result in an increased or 
decreased digoxin concentration; use with 
caution and with appropriate monitoring of 
serum digoxin concentrations.
Herbal/Natural 
SupplementsSt. John’s w ort, Echinaccea, Milk thistle 
(i.e.silymarin), Chinese herb sho -saiko -to 
(or Xiao -Shai-Hu-Tang
Others Probenecid
F/TAF
Protocol GS -US-311-[ADDRESS_1280625] of Prohibited Medications with Adverse Skeletal Effects
Medication Class Prohibited Medications
Cyclophosphamides / Cytophosphanes cytoxan, endoxan, neosar, procytox, revimmune
Ciclosporins cyclosporine A, B, C, D, E, F, and G
Glucocorticoids Chronic, systemic glucocorticoids
Medroxyprogesterones Depo-Provera
Additionally , Investigators should refer to the product/package inserts of the other ARV
medications for age -related recommendations or contrain
dications related to their use.
5.5. Accountability
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP . 
This includes acknowledgement of receipt of each shipment of I MP (quantity  and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
F/TAF accoun tability  records will be provided to each stud y site to:
Record the date received and quantity  of IMP kits
Record the date, subject number, subject initials, the IMP kit number dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information.
5.6. I nvestigational M edicinal Product Return or Disposal
Refer to Section 9.1.7 for detailed instructions. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280626]’s clinical chart and
electronic Case Report Forms (eCRFs) .
In addition, the Sponsor or Contract Research 
Organization (CRO) should be promptly  notified of any important protocol deviations.
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the I nvestiga tor to ensure that each subject is eligible for the study  
before enrollment.
Please refer to Section 5.1for details about subject number and treatment assignment for each 
Cohort.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 3 5days before Baseline/Day  1to determine eligibility  for 
participation in the study .The following activities will be performed and documented during
screening: 
Obtain written informed assent/ consent
Each subject must sign an assent if they  have the ability  to read and write (and parent or legal 
guardian sign an informed consent form) prior to the conduct of an y screening procedures. 
Subjects will be assigned a screening number at the time of assent/consent. Screening 
evaluations are used to determine the eligibility  of each candidate for study enrollment. 
Obtain medical and medication history , including history  of: 
Review of Concomitant Medications
■Any ongoing medications within 30 day s of the Screening visit
HIV-1 disease -related events 
Historical genot ypes should be collected, if available.
Complete phy sical examination (urogenital/anorectal examination will be performed at the 
discretion of the investigator)
Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature)
F/TAF
Protocol GS -US-311-[ADDRESS_1280627] 2017Weight and height /length
12-lead ECG performed supi[INVESTIGATOR_050] 
Urine collection for the following laboratory  procedures:
Urinaly sis 
Blood sample collection for the following laboratory  anal yses:
Serum pregnancy  test (
for females of childbearing potential in Cohorts 1 & 2 only ).If 
the test is positive, the subject will not be enrolled.
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric a cid, and amy lase 
(reflex lipase testing is performed in subjects with total amy lase > 1.5 × ULN)
Hematology  profile: complete blood count (CBC) with differential and platelet count
Estimated Glomerular Filtration Rate (eGFR )using Schwartz Formula:
■(mL/min/1.7 3 m2) = k ×L/S Cr(k is a proportionality  constant, L is height in 
centimeters (cm) and SCris serum creatinine (mg/dL)). 
○ The value of k is 0.55 for children ( ≥ 2 to < 12) and adolescent girls 
(
≥ 12 yearsold) and 0.7 for adolescent boy s (≥ 12 y ears old).
Plasma HIV -1 RNA 
CD4 cell count and percentage
Hepatitis B virus (HBV) surface antigen serology  (HBsAg)
Hepatitis C virus antibody  (HCVAb) serology
■Note: If the antibod y test result is positive, HCV RNA test will be performed to 
confirm HCV viremia.
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form.
F/TAF
Protocol GS -US-311-[ADDRESS_1280628] [ZIP_CODE].2.2. Baseline /Day 1 Assessments
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 35 days after the Screening visit for the Baseline/Day  1visit .
Subjects with exclusionary screening laboratory  results due to an acute clinical condition which 
resolves can be re -
screened within [ADDRESS_1280629] all serious adverse events (SAEs), as well as an y 
non-serious adverse events related to protocol -mandated procedures on t he adverse events case 
report form (CRF/eCRF). All other untoward medical occurrences observed during the screening 
period, including exacerbation or changes in medical history  are to be captured on the medical 
history  CRF/eCRF. Refer to Section 7,Adverse Events and Toxicity  Management ,for additional 
details. 
The following 
items and evaluations are to be completed at the Baseline/Day [ADDRESS_1280630] complete all Baseline /Day  1procedures before being dispensed the study  drug. Initiation of 
treatment with the study  drug must take place within 24 hours after the Baseline /Day 1visit.
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator ) 
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature)
Weight and h eight /length
Tanner Stage assessment
DXA Scan of the lumbar spi[INVESTIGATOR_911703]:
The DXA scan will be performed on subjects once eligibility  is confirmed and prior to 
study  drug administration at the Baseline/Day  1 Visit. The scan may  be performed on the 
morning of the Baseline/Day  1 Visit as long as it occurs before dosing.
Urine collection for the following laboratory  procedures:
Urinaly sis
Urine Chemistry
F!TAF 
Protoco l GS- US-[ADDRESS_1280631] ( collected faste d for Coho1is 1 and 2) including retinol binding 
protein and beta-2-microglobu lin. If the su bject has not fasted prior to the visit, the visit 
may continue; howeve r, the su bject must return within [ADDRESS_1280632] (females of childbea ring potential in Cohort s 1 & 2 only). If the 
urine pregna ncy test is positive at Baseline /Day 1, study dmg will not be dispensed. The 
positive result will be confomed with a sennn pregna ncy test. If the semm pr egnancy test 
is positive the su bject will not be able to parti cipate. 
• Blood sample collectio n for the following laborato 1 y analyses: 
-Chemistiy profile: alkaline phosphatase , AST , ALT , total bilimbin, direct and indirect 
bilimb in, total prote in, albumin , CPK, bicarbonate, BUN, calcium, chloride, creatin ine, 
glucose, phosphoms, magnesium , potassium, sodium , uric acid, and am ylase 
(reflex lipase testing is perfo1med in subjects with total amylase > 1.[ADDRESS_1280633]). 
-Metabolic assessme nts: Fasting (no food or dr inks, except wate r, at least 5 hours prior to 
blood collectio n) glucose and lipid panel (total cholesterol, HDL , direct LDL, and 
ti·iglycerides) for Coho1 i s 1 and 2 (all groups). If the su bject has not fasted prior to the 
visit, the visit may continue; however, the su bject must return within 72 hours in a fasted 
state to draw blood for the metabo lic assessme nts. The fasting requireme nt for 
Coho1is 3 and 4 will be speci fied in a future protoco l amendment. 
- H emato logy profi le: complete blood count (CBC) with differe ntial and platelet count 
-Plasma HIV-1 RNA 
-CD4 + cell count and perce ntage 
-Whole blood sample storage for virology testing 
-Semm will be collected for bone safety tests 
( collected fasted) , including bone speci fic 
alkaline phosphatase (BsAP), sennn phosp horous, P lNP, CTX , PTH , 1,25-[ADDRESS_1280634] has not fasted prior to the visit, the visit 
may continue; howeve r, the su bject must return within [ADDRESS_1280635] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280636] 2017Assign subject number :
The subject’s enrollment number can be assigned via IWRS up to 7 days prior to the 
Baseline/Day [ADDRESS_1280637] 
eligibility  has been confirmed.
Study  drug dispensation :
Study  drug will be dispensed in an open -label fashion. Subjects and/or parent/guardian will 
be dispensed F/TAF based on cohort, their weight and their 3rdagent . Subjects should initiate 
dosing of stud y drug within 24 hours after the Baseline /Day  1visit.Investigators will provide 
prescriptions to the subject s and/or parent/guardian for the ir3rdARV agent. The subject s
and/or parent/guardian areresponsible for obtaining the ir3rdARV agent
prior to the 
Baseline/Day  1 visit .
Subjects and/or parent/guardian should be instructed to take study  drug along with the
subject’s 3rdARV agent once dail ywith or without food as determined by [CONTACT_941] 
3rdARV agent
andat approximately  the same time each day . The subject and/or parent/guardian should be 
counseled regarding the importance of adherence and taking alltheir 
ARV study  medication 
at approximately  the same time each day .Sites should consider individual subject study  drug 
dosing schedule s while scheduling stud y visits requiring collection of PK samples.
Study  drug accountability :
Subjects and/or parent/guardian should be reminded to bring the irdrug bottles of the F/TAF
and their 3rdARV agent with them for drug accountability at Week 1.
6.3. Treatment Assessments through 48Weeks ( Weeks 1 (Day 7) − 48)
The following evaluations are to be completed at the end of Weeks 1(Day 7) , 2, 4, 8, 12, 24, 36, 
and 48unless otherwise specified.
All study visits are to be scheduled relative to when the Baseline/Day 1 visit was completed .
Thereafter all study  visits through Week 8 are to be completed within ± 2 day s of the protocol
specified visit date. Visits 
between Week 12 through Week 48are to be completed within 
± 4days of the protocol specified visit date, unless otherwise specified.
Regularly  scheduled evaluations will be made on all subjects whether or not they  continue to
receive study  drug.
Review of AEs and changes in concomitant medications
Complete phy sical examination (Weeks 24 and48)(urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or sy mptom -directed phy sical examination as 
needed (Week (s) 1 (on Day 7), 2, 4, 8, 12, and 36)
F!TAF 
Protocol GS-US-311-1 269 
[COMPANY_009] Sci ences, Inc. 
• V ital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperatur e) 
• W eight and height/length Final 
Amendment 2 
• Tanner Stage assessment (\Vee ks [ADDRESS_1280638] 
achieved Tanner Stage 5) 
• DXA Scan of the lumbar s pi[INVESTIGATOR_911704] 24 and 48 (± 10 days) 
• Ur ine collection for the followin g labo rato1 y procedures: 
- Ur inalysis 
-Urine chemistry (\Vee ks 2, 4, 8, 12, 24, and 48) 
-Selected renal safety test ( co llected fasted for Coho1 i s 1 and 2) includin g retino l binding 
protein and beta-2-microglobulin. If the s ubject has not fasted prior to the visit, the vis it 
may continue; however, the su bject must return within [ADDRESS_1280639] (\Vee ks 2, 4, 8, 1 2, 24, a nd 48). 
- Ur ine pregnanc y test (females of chi ld bearing potential in Cohort s 1 & 2 only). If the 
urine pregnancy test is p ositive, s tudy dmg will not be dispensed. The p ositive result will 
be confnmed with a sernm pr egnancy test. If the s ernm pregnanc y test is p ositive the 
subject will be discon tinued. 
• Bl ood co llection for the following labo rato1y procedures: 
-Chemi stiy profile: alkaline ph osphatase, AST, ALT , total bilimbin , direct and indirect 
bilirnb in, total protein, albumin , CPK , bicarbonate, BUN, calcium, chlor ide, crea tinine, 
glucose, ph osphorns, magne sium, potassium, sodium , uric acid, and amylase 
(reflex lipase testing is perfo1med in subjects with total amylase > 1.[ADDRESS_1280640]). 
-Metab olic assess ment s: Fasting (no food or drink s, except water, at least 5 ho urs prior to 
blood collection) g lucose and lipid panel (total cholesterol , HDL, direct LDL, and 
ti· iglycerides) for Coho1 i s [ADDRESS_1280641] has not fasted prior to the visit, the vis it 
may continue; however, the su bject must return within 72 hours in a fasted state to draw 
blood for the metabolic assessments. F asting requirement for Coho1 i s 3 and 4 will be 
specifi ed in a future protocol amendme nt (\Veeks 24 and 48). 
- H emato logy profi le: co mplete blood count (CBC) with differe ntial and platelet count 
-Plasma HIV-I RNA 
CONFID ENTIAL Page [ADDRESS_1280642] 2017 
F!TAF 
Protoco l GS-US-31 1-1269 
[COMPANY_009] Sciences , Inc. 
-CD4+ cell count and percentage 
I Final 
Amendment2 
-Sernm for bone safety tests ( collected fasted) , includin g bone specific alkali ne 
phosphatase (BsAP) , sernm phosphorous , PlNP , CTX , PTH , 1,25-OH vitamin D, and 
25-OH vitamin D. If the subject has not fasted prior to the visit, the visit may continue; 
however, the subject must return within 72 hours in a fasted state to draw blood for bone 
safety tests (for Cohort 1: Weeks 4, 12, 24, and 48 (±6 days); for Cohorts 2,3, and 4: 
Weeks 8, 12, 24, and 48 (±6 days)) 
-eGFR accor ding to Schwaiiz fo1mula 
• Diaiy cai· d dispensation: 
-Coho1i 1: Dispense subject diaiy cai·ds for subject to record administration of study mugs 
and their 3rd ARV agent for at least 3 days prior to the IPK visit (Week 2). 
-Coho1is 2, 3, a nd 4, Paii A: Dispense subject diaiy cards for subject and/or 
pai· ent/guai·dian to record amninistratio n of study mugs and their 3rd ARV agent for at 
least 3 days prior to the IPK visit (Week 2 or 4). 
• Study mug dispensation: 
-In-clinic dosing will occur at Weeks 2, 4, 8, and 12 
-Document study mug dispensation for all study mugs dispensed (Weeks 4, 8, 12, 24, 36, 
and 48 [Week [ADDRESS_1280643] 
Week 48]). 
-The subject should be counseled regai·d ing the importance of adherence and taking their 
study medication and their 3rd ARV agent, on ce daily, at approximately the same time 
each day as directed by [CONTACT_12244] r. Sites shou ld consider individual subject study 
mug dosing sched ules while scheduling study visits requiring collection of PK samples. 
• Study mug accountability: 
- Su bjects and/or pai·ent/guai ·dian should be reminded to bring their mug bottles of the 
F/TAF and their 3rd ARV agent with them to each visit for mug accountability 
(Weeks 1, 2, 4, 8, 12, 24, 36, and 48). 
• Su bjects who meet the criteria for rebound should be managed accord ing to Management 
Virologic Failure Section 6.10. 
CONFIDENTIAL Page [ADDRESS_1280644] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280645] 2017PK Blood Collection:
Intensive PK: 
■ IPK s amples will be collected for IPK evaluation for fasted subjects in Cohort 1
during the Week 2 visit andfor fasted subjects in Cohort 2 Part Aduring either the 
Week 2 or the Week 4 visit or within 7 day s after the c ompletion of Week 2 or the 
Week 4visit, as detailed in the PK m anual . The protocol will be amended prior to 
Cohorts 3 and 4 screening. The IPK collection schedule and fasting requirement for 
Cohorts 3 and 4 will be specified in a future protocol amendment . 
■ Details of the IPK blood sampling procedures, and sample management will be 
documented in the Pharmacokinetic Sample Collection, Processing, Storage, and 
Shipment Manual (PK manual). Subject diary  cards will be provided to subjects
and/or parent/guardia nto record administration of study  drugs and their
3rdARV agent for at least 3 day s prior to the PK visit. 
■Subjects and/or parent/guardian should be instructed prior to the IPK visit that on the 
day of IPK evaluation sthey should be fasted and that theirdose of F/TAF and their 
3rdARV agent must not be taken prior to the visit .This is not applicable to the visits 
when the random PK sample is drawn.
■If the subject has alread y dosed prior to the IPK evaluation visit or is not in a fasted 
state,the IPKassessments must not be completed . The subject should be instructed to 
return in a fasted state anytime within 7 day sand to return completed Diary Cards .
■If dosing non -compliance not related to AEs is identified on or prior to the IPK 
evaluation visit, t he IPK assessments must not be completed. The subject should be 
counseled regarding proper dosing and be scheduled to return for the IPK evaluation 
visit no sooner than 3 days following compliant dosing and within 7daysand to 
return completed Diary  Cards.
■In both scenarios described above the subject and/or parent/guardian should be 
reminded again to be fasted and to not take the F/TAF or their 3rdARV agent prior to 
arriving at the clinic on the day  of the re -scheduled I ntensive PK visit. 
■ Subject dosing diaries will be collected and reviewed on the day  of the IPK study  
visit.
F/TAF
Protocol GS -US-311-[ADDRESS_1280646] 2017Single PK: 
■Cohort 1: A single random PK sample will be collected at Weeks [ADDRESS_1280647] dose during Weeks 4 and 12 and a trough PK sample at 0 hours
(pre-dose, ≤ 30 minutes prior to dosing) during the Week 8visit.
■ Cohorts 2, 3, and 4: A single random PK sample will be collected at Weeks [ADDRESS_1280648] dose during Weeks 4 and 12 (Note: Single observed dosing PK 
sample does not need to be collected at Week 4 if Intensive PK is also collected at the 
Week 4 visit) . Trough PK sampling w ill be performed at the Week 8 visit at 0hours 
(pre-dose, ≤ 30 minutes prior to dosing) .
Palatability  and Acceptability  Assessment:
Cohort 1: At the Week 2 visit palatability  will be assessed 30 -60 minutes after study  
drug dosing for all subjects 
undergoing IPK sampling. Acceptabilit y will be assessed 
30 - 60 minutes after study  drug dosing for active subjects at the next study visit 
immediately  following approval of this protocol at the site.
Cohorts 2 Part A: Palatability  and acceptability  will b e assessed at the Week 2 or Week 4 
visit, or within 7 day s after the completion of the Week 2 or Week 4 visit,
30 - 60 minutes after study  drug dosing for all sub jects undergoing IPK sampling. 
Cohorts 3 and 4 Part A: Palatability  and acceptability  will be assessed for subjects 
undergoing I PK sampling. Assessment schedule will be 
specified in a future protocol
amendment.
PBMC Collection (at centers that have PBMC processing capability ):
Cohorts 1 and 2 : PBMC collection will be performed during the Week 8 visit only at 
study sites that can perform PBMC processing.
Cohort
s3 and 4: PBMC collection schedule will be specified in a future protocol
amendment.
For PK profiling in PBMCs, blood samples w ill be collected at 0 hours (≤ 30 minutes
pre-dose). Details of PBMC collection and processing will be documented in the PK 
manual .
F!TAF 
Protocol GS-US-311-1269 
[COMPANY_009] Sciences , Inc. 
6.4. Early Study Drug Discontinuation (ESDD) Final 
Amendme nt2 
If a subject discontinu es study drng prior to Week 48, t he subject will be asked to return to the 
clinic within 72 hours of sto ppi[INVESTIGATOR_911705]. Subj ects will then be asked to 
continue attending all scheduled study visits. Subjects who are no long er takin g study chug at 
Week 48 are not e ligible to parti cipate in the study extension. 
At the ESDD Visit , any evaluations showing abnormal results for which there is a possible 
or probable causal relationship with the study drug, should be repeated weekly ( or as often 
as deemed prudent by [CONTACT_093]) until the abnormality is resolved , returns to 
baseline, or is otherwise explained. 
The following evaluations are to be completed at the ES DD visit: 
• R eview of AEs and concomitant medications 
• Comple te physical examinati on (urogenital/anorectal exams will be perfo1med at the 
discretion of t he Investigator) 
• V ital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature) 
• Weight and heigh t/length 
• 12 -lead ECG perfo1med supi[INVESTIGATOR_050] 
• Urine collection for the following procedures: 
-Urinalysis and urine chemistiy 
-Urine pregnan cy test (for females of c hildbearing potential in Coho1is 1 and 2 only). The 
positive res ult will be confomed with a sennn pregnan cy test. 
- S elected renal safety test, includin g retinol bindin g protein and beta-2-microglobulin 
(renal safety tests required if last test was acquired > 12 weeks from the date of t he 
ESDD Visit (collected fasted for Coho1is 1 and 2). If the subject has not fasted prior to 
the visit, the visit m ay continue; howeve r, the subj ect must return within [ADDRESS_1280649]). 
CONF IDENTIAL Page [ADDRESS_1280650] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280651] 2017Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amy lase 
(reflex lipase testing is performed in sub jects with total amy lase > 1.5 × ULN)
eGFR according to Schwartz formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4 cell count and percentage
Plasma HIV -1 RNA 
Serum storage sample for possible additional testing
Serum will be collected for bone safety  tests (collected fasted), including bone specific 
alkaline phosphatase (BsAP), serum phosphorous, 
P1NP, CTX, PTH , 1,25-OH vitamin 
D
,and 25-OH vitamin D.If the subject ha s not fasted prior to the visit ,the visit may  
continue, however the subject must return within 72 hours in a fasted state to draw blood 
for bone safet y tests.
DXA scan (lumbar spi[INVESTIGATOR_456000] ) required if last scan was acquired > 12weeks from 
the date of the ESDD Visit. DXA scan can occur up to 10 days after the ESDD Visit. 
Drug accountability
6.5. 30- Day Follow -Up Visit
Subjects who discontinue study  drug prior to Week 
48will be required to return to the clinic 
30days after completion of an ESDD visit for a [ADDRESS_1280652] one subsequent 
visit after the Earl y Study Drug Discontinuation Visit will not be required to complete the 
30-Day Follow -Up visit.
Subjects who complete 48weeks on stud y drug and do not enroll in the extension phase of the 
study  will be required to return to the clinic 30 days after completion of the Week 48visit for a 
30-Day Follow-up visit.
For the purpose of scheduling a 30 -Day Follow -Up visit, a ± 6 day s window may  be used.
CCI
F!TAF 
Protocol GS-US-311 -1269 
[COMPANY_009] Sciences , Inc. 
The following evaluations are to be completed at the 30-Day Follow-Up visit: 
• Review of AEs and concomita nt medicat ions 
• Symptom -directed physical examinatio n 
• Vital signs (blood press ure, pulse, respi[INVESTIGATOR_1487], and temperature) 
• Weight and height/length 
• Ur ine collectio n for the following procedures: 
- Ur inalysis Final 
Amendment2 
- Ur ine pregnancy test (for females of childbea ring potential only for Coho1is 1 and 2). 
A posit ive result will be confnmed with a sernm pr egnancy test. 
I 
• DXA scan (lumbar spi[INVESTIGATOR_456000]) required if last scan was acquired > 12 weeks from 
the date of the 30 day follow-up Visit. DXA scan can occur up to 10 days after the 30 day 
follow-up Visi t. 
• Bl ood sample collectio n for the following laborato 1 y analyses: 
-Chemistiy profile: alkaline ph osphatase , AST , ALT, total bilirnbin, direct and indirect 
bilirnb in, total protein , albumin , bica rbonate , BUN , calcium , chloride, creat inine, 
glucose, phosphorns, magnesium , potassium, and sodium, CPK, and uric acid 
-eGFR accor ding to Schwaiiz fo1m ula 
- H emato logy profi le: complete blood count (CBC) with differential and platelet count 
-CD4+ cell count and percentage 
-Plasma HIV-[ADDRESS_1280653] ing 
At the 30-Day Follow -Up visit, any evaluations sh owing abno1 m al r esults for which th ere is a 
possible or probable causal relationsh ip with the study diug. should be repeated weekly ( or as 
often as deemed prnde nt by [CONTACT_31691]) until the a bno1ma lity is resolved, returns to 
baseline , or is othe1wise explained. 
CONFIDENTIAL Page [ADDRESS_1280654] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280655] Week 48 Assessments (every 12 weeks)
Subjects will receive their assigned treatment for 48weeks. After completion of 48weeks of 
study  treatment , all subjects will be given the option to participate in an extension phase of the 
study .[COMPANY_009] will provide F/TAF until a)the subject turns 18 years old and F/TAF is 
commerciall y available for use in adults in the country in which the subject is enrolled or
b)F/TAF becomes commerciall y available for pediatric use in the country in which the subject is 
enrolled or c)[COMPANY_009] Sciences elects to terminate development of F/TAF in the applicable 
country .Subjects who are no longer taking study  drug at Week 48are not eligible to participate 
in the study  extension. 
Subjects who choose to participate in the extension phase will return for study  visits 
every 12weeks (± 10 days ).
The following evaluations are to be completed at each study  visit unless otherwise specified:
Review of AEs and concomitant medications
Tanner Stage assessment (every 12weeks except for subjects documented to have 
achieved Tanner Stage 5)
Either a symptom -directed phy sical examination every  12 weeks or a complete physical 
examination a
tevery  48weeks ( urogenital/anorectal exams will be performed at the 
discretion of the Investigator).
Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature) 
Weight and height /length
12 lead ECG performed supi[INVESTIGATOR_911706]  48 weeks 
Urine collection for the following procedures:
Urinaly sisUrine Chemistry (every 
12 Weeks)
Urine pregnancy  test (females of child bearing potential only).If the urine pregnancy  test 
is positive, study  drug will not be dispensed. The positive result will be confirmed with a 
serum pregnancy  test. If the serum pregnancy  test is positive the subject will be 
discontinued from the study .
Urine sample storage for possible additional testing (urine chemistry  including urine 
phosphorus and urine creatinine)
Selected renal safety  tests (collected fasted for Cohorts 1 and 2) , including retinol binding 
protein and beta -2-microglobulin .If the subject has not fasted prior to the visit ,the visit 
may continue; however, the subject must return within [ADDRESS_1280656] (every 12 Weeks) .
F/TAF
Protocol GS -US-311-[ADDRESS_1280657] 2017Blood sample collection for the following laborator y analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, and a mylase 
(reflex lipase testing is performed in subjects with total amy lase > 1.5 × ULN) .
Metabolic assessments: Fasting (no food or drinks, except water, at least 5hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides) for Cohort s1 and 2. If the subject has not fasted prior to the visit, the visit 
may continue; however, the subject must return within 72 hours in a fasted state to draw 
blood for the metabolic assessments (every 24Weeks) . Note that glucose anal ysis will be 
done as part of the fasting metabolic assessments and n ot as part of the chemistry  profile , 
every  24weeks post week 96
Serum will be collected for bone safety  tests (collected fasted), including bone specific 
alkaline ph osphatase (BsAP), serum phosphorous, 
P1NP, CTX, PTH , 1,25-OH vitamin 
D
,and 25-OH vitamin D will be performed at every  12weeks (±10 day s) thereafter. If 
the subject has not fasted prior to the visit, the visit may  continue; however, the subject 
must retur n within 72 hours in a fasted state to draw blood for bone safet y tests
(every 24Weeks)
Plasma sample storage for virology , safet y, and/or PK testing (every 12 weeks)
eGFR according to Schwartz formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4 cell count and percentage
Plasma HIV -1 RNA 
DXA scans of the lumbar spi[INVESTIGATOR_911707] (every 24 Weeks ± 10 days)
Study  drug dispensation :
Subjects and/or parent/guardian should be instructed to take study  drugs with or without 
food as determined b y their 3rdARV agent. The subject and/or parent/guardian should be 
counseled regarding the importance of adherence and taking their study  medication at 
approximately  the same ti me each day  as directed by  [CONTACT_737].
Study  drug accountability :
Subjects and/or parent/guardian should be reminded to bring the required drug bottles of 
the F/TAF and their 3rdARV agent with them for drug accountability .
F!TAF 
Protocol GS- US-311-1269 
[COMPANY_009] Sci ences, Inc. 
6.7. Bone Evaluation s Final 
Amendment 2 
For a ll subjects DXA scans will be perfo1med prior to study diug adininistration at the 
Baseline/D ay 1, at Week s 24 and 48 (::1:10 days), followed by [CONTACT_911727]1y [ADDRESS_1280658] W eek 48 
(::1:10 days), and the Early Study Drng Discontinuation Visit (if applicable) up to 10 days after the 
ESDD visit date. Scan s will cover the lumbar sp ine and total body to measure chan ges in bone 
mineral density (BMD). DXA scan results will be provided to study sites. 
A complete description of the procedure s perfo1med for the DXA scans wi ll be provided in a 
DXAmanu al. 
6.8. Bone and Renal Safety Evaluation s 
For su bject s in Coho1i 1, the following bone sa fety tests will be collected (fasted) at 
Baseline /Day 1 and Weeks 4, 12, 24, and 48 (±6 days), followed by [CONTACT_92538] e1y [ADDRESS_1280659] 
Week 48 (::1:10 days): BsAP, PlNP, CTX, PTH , 1,25-OH vitamin D, and 25-OH vitamin. 
For su bject s in Coho1i 2, 3, and 4, the following bone s afety tests wi ll be collected (fasted) at 
Baseline/D ay 1 and Weeks 8, 12, 24, and 48 (±6 days), followed by [CONTACT_92538] e1y [ADDRESS_1280660] 
Week 48 (::1:10 days): BsAP, PlNP, CTX , PTH , 1,25-OH vitamin D, and 25-OH vitamin. 
For a ll subjects, urine will also be collected for selected renal safety tests, including urine 
chemistiy, retinol binding prote in, and beta-2-inicro globu lin at the B aseline /Day [ADDRESS_1280661] Week 48 (::1:10 days). 
Bone and r enal safety test assessment s will be collected fasted. If the subject has not fasted prior 
to the vis it, the visit m ay continue; however, the su bject must return within 72 hour s in a fasted 
state to di· aw blood for bone safety tests and provide a urine sample for renal s afety tests. 
CONFID ENTIAL Page [ADDRESS_1280662] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280663] [ZIP_CODE].10. Virologic Failure and Management of Virologic Rebound
Subjects who experience virologic rebound (VR), as defined below, will be considered to have 
virologic failure. 
If the viral load is ≥ 50 copi[INVESTIGATOR_014]/mL , HIV -1 RNA should be repeated at a scheduled or 
unscheduled visit ([ADDRESS_1280664] with HIV -1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL ).
Subjects will be considered to have virologic rebound if they  have confirmed H IV-1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL  (two consecutive tests) at scheduled or unscheduled visits.
Upon confirmation of HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL, potential causes of virologic failure should 
be documented. Assessments should include:
Review treatment adherence with subject and/or parent/guardian
Review of AEs and concomitant medications
Comorbidities (eg, active substance abuse, depression, other intercurrent illnesses)
If virologic rebound is confirmed at the scheduled or unscheduled visit, and the HIV -1 RNA 
value is ≥ 400 copi[INVESTIGATOR_014]/mL, the blood samples from the confirmation visit will be used for HIV -1 
genot ype/phenot ype testing.
If genot ype/phenot ype resistance to study  drug is documented, study  drugs should be 
discontinued. 
If no resistance is detected from genot ype/ph enotype testing, subject may  remain on study  drug 
and the HIV -1 RNA testing should be repeated ([ADDRESS_1280665] with 
viral load ≥ 50 copi[INVESTIGATOR_014]/mL) until <50 copi[INVESTIGATOR_014]/mL is achieved or the subject discontinues. 
Subjects experiencing virologic failure due to emergent resistance on study , but whose virus
remains sensitive to FTC and TFV will be permitted to switch to a new fully active 
3rdARV agent and remain on their F/TAF -containing regimen. Subjects unable to tolerate 
current 3rdagents due to clinically  significant toxicities will be permitted to switch after 
consultation with the medical monitor to a new fully  active 3rdARV agent and remain on their 
F/TAF -containing regimen.
Investigators should carefully  evaluate the benefits and risks of remaining on study  drug for each 
individual subject and document this assessment in the on site medical record. Investigators who 
opt to discontinue study  drugs for an individual subje ct must discuss with the 
[COMPANY_009] Medical Monitor prior to st udy drug discontinuation. 
Please refer to Figure 6-1for the management of subjects who meet the criteria for virologic 
rebound.
F/TAF
Protocol GS -US-311-[ADDRESS_1280666] will remain on their current regimen
b
If virologic rebound is confirmed, and the HIV-1 RNA is ≥ 400 copi[INVESTIGATOR_014]/mL, the HIV -1 genotype and phenotype 
(reverse transcriptase and protease) will be analyzed
c Based on the results of the geno type/phenotype assays, the subject will remain on study drugs, or study drugs will be 
discontinued. If genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_580868], a new ARV regimen may be configured at the discretion of the Investigator
d If no resistance detected, HIV -1 RNA will be re peated (2 -4 weeks later) until < 50 copi[INVESTIGATOR_014]/mL is achieved or the subject 
discontinues . Investigator is to review and discuss study drug continuation/discontinuation options with Medical Monitor 
prior to study drug discontinuation
e A new ARV regimen will b e configured, at the Investigator’s discretion, and the subject will remain in the study
6.10.1. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -[ADDRESS_1280667] HIV -1 RNA ≥ 400 copi[INVESTIGATOR_014]/mL  at Week s [ADDRESS_1280668] visit while 
receiving stud y drugs (within 72 hours of discontinuation of study treatment) will be anal yzed 
for resistance.
         
          
     
    
       
   
  
  
   
   
  
 
            
           
           
F/TAF
Protocol GS -US-311-[ADDRESS_1280669] [ZIP_CODE]. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a pharmaceutical product, which does not necessaril y have a causal relationship 
with the treatment. An AE can therefore be an y unfavorable and/or unintended sign, s ymptom, or 
disease temporall y associated with the use of a medicinal product, whether or not considered 
related to the medicinal product. AEs may  also include pre-or post-treatment complications that 
occur as a result of protocol specified procedures, lack of efficacy , overdose, drug abuse/misuse 
reports, or occupational exposure. Preexisting events that increase in severity  or change in nature 
during or as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusion. 
The condition that led to the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_911708] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not relate d to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the follow ing:
Death
Life-threatening (Note: The term “life -
threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death i f it were more severe.)
In-patient hospi[INVESTIGATOR_1081]
F/TAF
Protocol GS -US-311-[ADDRESS_1280670] 2017Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_82221]. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and developmen t of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements. 
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities ( e.g., clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments ( e.g., electrocardiogram, x -rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.[ADDRESS_1280671] the s yndrome or diagnosi s (e.g., anemia), not the 
laboratory  result ( i.e., decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Appendix 3.
7.2. Assessment of Adverse Events and Serious Adverse Events
The I nvestigator or qualified 
Sub-investigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
T
he investigator or qualified sub-investigator is responsible for assessing the relationship to IMP 
therap y using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an
alternative causality  must be provided ( e.g., pre-existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes: There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
F/TAF
Protocol GS -US-311-[ADDRESS_1280672] 2017It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures ( e.g., invasive procedures such as venipuncture or biops y) 
should be assessed u sing the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures ( e.g., venipuncture)
7.2.2. Assessment of Severity
Severity  should be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalitie s (Appendix 4).For adverse events associated with 
laboratory  abnormalities, the event should be graded on t
he basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009] 
Requirements for C ollection Prior to Study D rug Initiation
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form (CRF/eCRF): 
all serious adverse events (SAEs) 
adverse events related to protocol -mandated procedures.
Adverse Events
Following initiation of study  medication, collect all AEs, regardless of cause or relationship, 
until [ADDRESS_1280673] be reported to the CRF/eCRF database 
as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
[COMPANY_009] Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or rel ationship, that occurs after the subject first consents to 
participate in the stud y (i.e., signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
CRF/ eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol -associated procedures performed after informed 
consent is signed. Any SAEs and deaths that occur after the post treatment follo w-up visit but 
within [ADDRESS_1280674] dose of study  IMP, regardless of causalit y, should also be reported. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280675] day on stud y (including 
the off -study  medication follow -up period) t he SAE has not resolved, then the SAE will be 
followed up until the investigator and/or [COMPANY_009] Sciences determine that the subject's condition is 
stable. However, [COMPANY_009] Sciences may  request that certain SAEs be followed until resolution.
Investigators are not obligated to activel y seek SAEs after the follow up 30- dayperiod. 
However, if the investigator learns of an y SAEs that occur after stud y participation has 
concluded and the event is deemed relevant to the use of IMP, he/she should promptly  document 
and report the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines 
outlined in the CRF/eCRF completion guideline . 
At the time of study  start, SAEs will be reported using an electronic SAE (eSAE) sy stem
using the Electronic Serious Adverse Event Reporting Process detailed below .[COMPANY_009] will 
provide training and account information prior to implementing an eSAE system.
The Serious Adverse Event Paper Reporting Process is to be used only  if the EDC Sy stem is 
not available .
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel will record all SAE data in the eCRF database and from there transmit the 
SAE information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the 
even t.Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , 
i.e.,theeCRF database is not functioning, record the SAE on the paper serious adverse event 
report ing form and submit within 24 hours as described above.
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been 
locked, no further action is necessary .
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , i.e., the 
eCRF database is not functioning, record the SAE on the paper serious adverse event 
reporting form and submit within 24 hours as described above.
As soon as it is possible to do so, any
 SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
F!TAF 
Protoco l GS- US-31 1-1269 
[COMPANY_009] Sciences , Inc. Final 
Amen dment 2 
• If an SAE has been reported via a paper fonn because the eCRF database has been locked, no 
further action is necessa 1y. 
• For fatal or life-threatening events , copi[INVESTIGATOR_449680]1ts, autopsy repo1 t s, and other 
documents are also to be submitted by e-mail or fax when requested and applicable. 
Transmissio n of such docume nts shou ld occur without personal subject identificatio n, 
maintain ing the trnceability of a docume nt to the subj ect identifiers . 
• Additio nal infonnation may be requested to ensure the timely comp letion of accurate safety 
repo1 t s. 
• Any medica tions necessaiy for treatme nt of the SAE must be recorded onto the concomitant 
medicat ion section of the subj ect's CRF /eCRF and the event descript ion section of the SAE 
fo1m . 
Serious Adverse Event Pape r Repo1t ing Process 
SAEs will be recorded on the serious adve rse event pape r report fo1m and su bmitted by [CONTACT_911728] r epo1t fo1 m within 24 hours of the Investigator 's knowledge of the event to the 
attention of [COMPANY_009] DSPH and the medical monitor: 
[COMPANY_009] Sciences Drng Safety 
Public Health (DSPH): 
[COMPANY_009] Sciences Med ical Mon itor: Fax: 
E-mail: 
Name: 
[CONTACT_10880]: 
Mobi le Phon e: 
Fax: 
E-mail: 
7.4. [COMPANY_009] Reportin g Requirem ents IPI[INVESTIGATOR_911709] n or r egulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Direct ive (2001/20/EC) and releva nt upda tes, and 
other countiy-spec ific legisla tion or regulations, [COMPANY_009] may be required to expedite to 
worldwide regulato1 y agencies reports of SAEs , serious adve rse drng reactions (SADRs), or 
suspected unexpected serious adverse reactio ns (S[LOCATION_003]Rs) . In accorda nce with the EU Clinical 
Trials Direct ive (2001/20/EC), [COMPANY_009] or a specified designee will notify worldwide regulato1 y 
agencies and the releva nt IEC in concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
cmTent regulations. 
Assessme nt of expectedness for SAEs will be dete1mined by [CONTACT_449716]1matio n specified in the investigato r's brochure or relevant local label as applicable. 
All investigators will receive a safety letter not ifying them of relevant S[LOCATION_003]R repo1 t s. The 
investigato r shou ld notify the IRB or IEC of S[LOCATION_003]R reports as soon as is practical, where this is 
required by [CONTACT_353890]1 y agencies, and in accordance with the local institutio nal policy. 
CONFIDENTIAL Page [ADDRESS_1280676] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280677] [ZIP_CODE].5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
7.5.1. Toxicity Management
All clinical an d clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3as outlined below.
All clinically  significant Grade [ADDRESS_1280678]’s safet y.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the GSI Grading Scale for Severit y of Adverse Events and Laboratory Abnormalities
(Refer toAppendix 4).
Any questions regarding toxicity  management sho
uld be directed to the 
[COMPANY_009] Medical Monitor.
[IP_ADDRESS]. Management of Bone Toxicity
As there is uncertainty surrounding the clinical significance and management of decreases in 
bone mineral densit y for HIV- [ADDRESS_1280679] who has a DXA scan that demonstrates a decrease from baseline or from the previous 
visit of ≥ 4% to have a repeat DXA within [ADDRESS_1280680] should be withheld until the toxicity  returns to ≤ Grade 2.
F/TAF
Protocol GS -US-311-[ADDRESS_1280681] 2017If a laboratory  abnormality  recurs to ≥ Grade [ADDRESS_1280682] may  be continued without dose interruption for a clinically  
non-significant Grade 3- 4 laboratory  abnormality  (e.g., CK elevation after strenuous exercise, or 
triglyceride elevation that is non -fasting or that can be medicall y managed) or a Grade 3-[ADDRESS_1280683] 
(unconjugated) bilirubin related to inhibition of UDP- glucuron yl transferase (UGT). In pediatric 
clinical trials, 58% of patients experienced Grade 3 to 4 elevations ( ≥ 3.2 mg/dL) in total 
bilirubin (Rey ataz US Prescribing Information 2013). As subjects in this study  who are taking 
ATV/r as their 3rdARV agent may  frequently  have atazanavir -associated h yperbilirubinemia, the 
management of graded laboratory  abnormalities described above in S ection 7.5is not appl icable 
for the management of graded h yperbilirubinemia in these subjects.
However, repeat testing should be done and alternative etiologies (e.g. acute hepatitis B or C) 
should be sought in the following subjects:
1) In those with elevation in conjugated (dir ect) bilirubin > 1.5 × ULN (i.e. direct 
hyperbilirubinemia), regardless of the hy perbilirubinemia grade, liver labs (total bilirubin, 
direct bilirubin, AST, ALT) should be repeated within [ADDRESS_1280684] bilirubin > 1.5 × ULN, 
which is deemed as clinically  not significant, should be followed according to the clinical 
judgment of the Investi gator.
2) In those with hepatic transaminase elevation, the graded AST or ALT abnormalities should 
be managed according to Section 7.5
F/TAF
Protocol GS -US-311-[ADDRESS_1280685] 2017Dose modification of atazanavir sulfate is not permitted. Subjects who experience unacceptable 
jaundice/scleral icterus due to atazanavir -associated hy perbilirubinemia can be discontinued 
from the study  at the discretion of the Investigator.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, mis use, overdose, and 
pregnancy  reports regardless of an associated AE. Also includes reports of adverse reactions in 
infants following exposure from breastfeeding, and reports of adverse reactions associated with 
product complaints and reports arising from o ccupational exposure.
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer. 
Abuse is defined as persistent or sporadic i ntentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is de fined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labeling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the Investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribu tion of the medicinal p roduct. 
7.6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The Investigator should report all pregnancies in the female subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow -up 
period, to [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy . Refer to Section 7.6.2 and 7.3and the CRF/eCRF completion guidelines for full 
instructions on the mechanism of pregna ncy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
F/TAF
Protocol GS -US-311-[ADDRESS_1280686] 2017Any premature termination of pregnancy  (e.g., a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within [ADDRESS_1280687] information is as follows: Email: 
and Fax: 
Pregnancies of female partners of male stud y subjects exposed to [COMPANY_009] or other study  drugs 
must also be reported and relevant information should be submitted to [COMPANY_009] DSPH using the 
pregnancy  and pregnancy
 outcome forms within [ADDRESS_1280688] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to [COMPANY_009] DSPH, fax number 
 or email 
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Recommendations.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be repor ted on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_1280689] of situations that involve study  IMP and/or [COMPANY_009] concomitant 
medications, but do not ap ply to non- [COMPANY_009] concomitant medications. 
Special situations involving non -[COMPANY_009] concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomita nt medication, the AE should be reported on the AE form. 
Any inappropriate use of medications prohibited by
 [CONTACT_569290] 
“misuse,” but may  be more appropriatel y documented as a protocol deviation.
Refer to Section 7.6.2 and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SA E report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
F/TAF
Protocol GS -US-311-[ADDRESS_1280690] [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objectives of this study  are:
To evaluate the PKof TAF in HIV-1 infected children and adolescents virologicall y 
suppre ssed on 2- NRTI - c ontaining regimen,
To evaluate the safet y and tolerability  of F/TAF through Week 24
The secondary  objectives of this study  are:
To evaluate the PK of TFV and FTC 
To evaluate the safety, tolerability ,andefficacy  of F/TAF through Week 48 .
8.1.2. Primary Endpoint s
The primary  endpoint s are:
The PK parameter AUC taufor TAF
Incidence of treatment -emergent SAEs and all treatment-emergent adverse events through 
Week 24 
8.1.3.
Secondary Endpoint s
The secondary  endpoints are:
PK parameters of C max, Clast, Cl/F, and V z/F for TAF, AUC tau, Cmax, and C taufor FTC and 
TFV
Incidence of treatment -emergent SAEs and all treatment-emergent adverse events through 
Week 48 
The percentage of subjects with HI V
-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Weeks 24 and48 as defined 
by [CONTACT_55257] -defined snapshot algorithm 
The change from baseline in CD4+ cell count (cells/μL ) and CD4+ percentage at 
Weeks 24and48
The palatability  and acceptability  of the age -appropriate F /TAF formulation
F!TAF 
Protocol GS-US-311 -1269 
[COMPANY_009] Sciences , Inc. -
I 
I 
I 
8.2. 
8.2.1. 
[IP_ADDRESS]. Anal ysis Convention s 
Anal ysis Sets 
All Enrolled 
The all enrolled analysis set includes all subjects who are e nrolled into the study. 
All enrolled analysis set is the primaiy analysis set for by-subject listings. 
[IP_ADDRESS]. 
[IP_ADDRESS].1. Efficacy 
Full Analysis Set Final 
Amendment2 
The full analysis set (FAS) will include a ll subjects who ai·e enrolled in the study and h ave 
received at least one dose of study medicat ion. 
[IP_ADDRESS]. 
[IP_ADDRESS].1. Safety Safety Analysis Set 
The safety analysis set will include a ll subjects who are e nrolled in the study and h ave r eceived 
at least one dose of study medicat ion. 
[IP_ADDRESS]. 
[IP_ADDRESS].1. DXA 
Tota l Body Less Head DXA Analysis Set 
The t otal body less head DXA analysis set will include all subjects who (1) are enrolled in the 
study , (2) have received at least one dose of study medicatio n, and (3) have non-miss ing total 
body less head BMD value for the baseline visi t. 
[IP_ADDRESS].2. Spi[INVESTIGATOR_911710] a ll subjects who (1) are enrolled in the study , 
(2) have received at least one dose of study medicatio n and (3) have non-miss ing spi[INVESTIGATOR_911711] t. 
CONFIDENTIAL Page [ADDRESS_1280691] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280692] [ZIP_CODE].2.1.5. Pharmacokinetics
[IP_ADDRESS].1. I PK Anal ysisSet
The I PKanalysis set will include all subjects who (1) are enrolled in Cohort 1 or Part A of 
Cohort
s 2(each group) , 3, and 4 for IPKevaluation ,(2) have received at least one dose of study  
medication and (3) have at least [ADDRESS_1280693] 
(e.g., FTC, TAF, and TFV ).The IPK anal ysis set will be used for ana lyses of intensive PK 
analytes of TAF, TFV, and FTC.
[IP_ADDRESS].2. PK Analy sis Set
The PK anal ysis set will include all subjects who (1) are enrolled into the study , 
(2)have received at least one dose of stud y medication and (3) have at least [ADDRESS_1280694] ( e.g.,FTC, TAF, and TFV). The PK anal ysis set 
will be used for analy ses of general pharmacokinetics.
[IP_ADDRESS].3. PBMC PK Analy sis Set
The PBMC PK anal ysis set will include all subjects who (1) are enrolled into the study , 
(2)have received at least one dose of stud y medication and (3) have at least [ADDRESS_1280695] descriptive 
methods.
Demographic summaries will include sex, race/ethnicity , and age.
Baseline data including body  weight, height
/length , body  mass index, HIV -1 infection, and 
enrollment distribution will be summarized.
8.5. Efficacy Analysis
Efficacy  endpoints results from each group or cohort will be descriptive in nature. 
8.5.1. Primary Analysis
The primary  efficacy  endpoint is the proportion of subjects with HIV
-1 RNA < 50 copi[INVESTIGATOR_014]/mL at 
Week 24 as defined b y the US FDA -defined snapshot algorithm using the full analy sis set (FAS).
Virologic outcomes will be summarized using frequency  counts and percentages. The 95% CI
for the percentage estimate for each group or cohort will be constructed using the Exact method. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280696] [ZIP_CODE].5.2. Secondary Analyses
The percentage of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 as defined b y the US 
FDA -defined snapshot algorithm will be summarized in the same manner as the primary  efficacy  
endpoint .
The change from baseline in CD4+ cell count and CD4 +percentage will be summarized by  [CONTACT_765], 
group, and cohort using descriptive statistics. 
8.6. Safety Analysis
All safet y anal yses will be performed using the safety  anal ysis set.
All safet y data collected on or after the date that the study  drug was first administered up to the 
date of last dose of study  drug plus [ADDRESS_1280697] dose of 
study  drug plus 30 day s will be included in data listings.
Safety
 results from each group and coh ortwill be descriptive in nature. F/TAF results from all
cohorts will be combined to d escribe the overall safety  profile of F/TAF in subjects 1 month to 
<[ADDRESS_1280698]’s extent of exposure to study  drug will be generated from the study  drug 
administration data. Duration of exposure to study  drug will be expressed as the number of 
weeks between the first and last dose of the study  regimen, inclusive, regardless of temporary  
interruptions in study  regimen administration. Exposure data will be summarized by  [CONTACT_19313] , 
c
ohort, and overall. Dosing information for individual subjects will be listed.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Treatment -emergent AEs are events that meet one of the following criteria up to 30 daysafter the 
permanent discontinuation of th e study  drug:
Events with onset dates on or after the first dose date of study  drug,
Events that result in permanent study  drug discontinuation.
Summaries (number and percentage of subjects) of treatment -emergent adverse events (b y SOC 
and PT) will be provided by  [CONTACT_19313] , cohort and overall. Additional summaries will include 
summaries for adverse events by  [CONTACT_479], Investigator’s assessment of relationship to study  drug, 
and effect on stud y drug dosing.
F!TAF 
Protocol GS-US-311-[ADDRESS_1280699] 
dose of study regimen plus 30 days, will be summ arized by [CONTACT_19313], coho1t and overa ll. If baseline 
data are missing, then any graded abno1mality (i.e., at least a Grade 1) will be considered 
treatment emer gent. The maximum toxic ity grade will be summ arized by [CONTACT_911729]1 y parameter. 
Labo rato1 y abno1malities that occm before the first dose of study regimen or after the subj ect has 
been discontinued from treatment p lus 30 days will be included in a data listing. 
8.6.4. Bone Mineral Density 
Z-scores (standard Z- scores and a djusted Z-scores) for spi[INVESTIGATOR_911712] b aseline in Z-scores will also be summ arized by 
[CONTACT_765], group and coho1 t . The adjustment method w ill be specified in the Statistical Analysis Plan. 
8.6.5. Bone and Renal Safety Evaluations 
Selected bone safety tests , including BsAP, PlNP , CTX, PTH , 1,25-OH v itamin D, and 25-OH 
vitamin D, w ill be summ arized by [CONTACT_16750]. 
For all subjects in all coho1ts, selected renal safety tests, including retinol bindin g protein, and 
beta-2-Inicroglobulin , will be summari zed by [CONTACT_765], group, and coho1 t us ing descriptive statistics. 
8.6.6. Tanner Stage Assessment 
The Tanner stage assess ment score will be summ arized by [CONTACT_15449], group, and coho1 t . 
8.6.7. Acceptability and Palatability 
Acce ptability and palatability will be summari zed by [CONTACT_15449], group, and coho1t. 
CONFIDENTIAL Page [ADDRESS_1280700] 2017 
F!TAF 
Protoco l GS-US-31 1-1269 
[COMPANY_009] Sciences , Inc. 
8.6.8. Other Safety Evaluations Final 
Amendment2 
Weight and height/length will be summa rized by [CONTACT_765]. Safety ECGs will be summ arized. 
Number and perce ntage of subjects with abnonnal safety ECG will be summari zed by [CONTACT_765], 
group, and cohort. 
8.7. Pharmacokinetic Analysis 
The conce ntrntion data ofTAF , FTC , and TFV (if applicable) over sampli ng time will be listed 
and SUilllllar ized using descriptive statistics by [CONTACT_911730]. PK parameters (e.g., AUC1au , 
AUC1ast , Cmax , Tmax, C1ast, T1ast, C1au, "-z., appa rent CL, appare nt V2, and T ½) will be listed and 
summa rized for analytes TAF , FTC, and TFV (as applicable) using descriptive statistics 
(e.g., samp le size, arithm etic mean, geometi· ic mean, coefficient of variation% , standard 
deviatio n, median , Ql , Q3, minimum , and maximum) by [CONTACT_911730]. Plasma 
concenti·at ions over time will be plotted in semi logarithmic and linear fo1mats as mean 
± standard deviation, and median (Ql, Q3). 
TAF expos ure PK parameter (i.e., AUC1au) achieved in pediati·ic subjects from Cohort 1 and 
Pait A of Coho1is 2 (Groups 1 and 2), 3, 4 will be compa red to historical adult data 
(ie, GS-US-311-1089) . 
An analysis of variance will be canied out for log-ti·ansfonned TAF AUC1au as a prima1y 
pai·ameter while other pha1macokinetic pai·ameters such as Cmax will be explored. T AF data from 
each coho1i will be compai·ed to Study GS-US-311-1089 adult popu lation PKT AF data by [CONTACT_911731] ( eg, A TV /r or other Pis/r) if applicable. If the lower bound of the 
90% CI of the geometi ·ic mean ratio (pediati ·ic subjects vs adult subjects) is above 70% for TAF 
AUC1au , the TAF dose will be confnm ed. 
In addit ion, the 95% CI of the geometi ·ic mean estimate of apparent CL and apparent V z of T AF 
will be prov ided. 
8.8. Acceptability and Palatability 
Acceptability and palatability for the age-appropr iate F/TAF FDC fo1m ulation will be 
summa rized. Treatine nt adhe rence will also be summa rized. 
8.9. Sample Size 
Cohort 1: Twenty-five subjects from Coho1 i 1 in the TAF h'eatme nt aim will provide at least 
90% power to tai·get a 95% confi dence interval within 60% and 140% of the geomeh'ic mean 
estimate of appa rent CL and appa rent V2 ofTAF , respectively , assuming a standai·d deviation of 
0.60 for CL and 0.58 for V2 (natural log scale) estimated from Study GS-US-292-[ADDRESS_1280701] 2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280702] 2017Cohort 2 (Group 1) Part A : At least 10 subjects on boosted ATV + F/TAF and 6 subjects on 
boosted L PV or DRV + F/TAF, compared with the population PK data from 44 adult subjects on 
boosted ATV + F/TAF and 87 adult subjects on boosted LPV or DRV + F/TAF in 
Study GS-US-311- 1089, respectivel y, will each provide at least 80% power to show the lower 
bound of a 90% CI of geometric mean ratio (pediatric subjects vs. adult subjects) great erthan 
70% for AUC t
auof TAF, assuming that the expected geometric mean ratios of TAF AUC tau
between pediatric subjects and adult subjects are equal to [ADDRESS_1280703] deviations are 0.40 
(with boosted ATV + F/TAF) and 0.33 (with boosted L PV or DRV + F/TAF) ng*hr/mL for TAF 
AUC tau(natural log scale) estimated from the population PK data in Study  GS-US-311-1089.
Part A of 
Cohorts 2 (Group 2), 3, and 4 : At least 10 subjects on boosted ATV + F/TAF and 
7subjects on an y other third agent + F/TAF in each group or cohort , compared with th e 
population PK data from the [ADDRESS_1280704] agent + DVY in Stud y GS-US-311-1089, 
will provide 90 % power to show the 
lower bound of a 90% CI of geometric mean ratio (pediatric 
subjects vs. adult subjects) great erthan 70% for AUC tauof TAF, assumi ng that the expected 
geometric mean ratio of TAF AUC t
aubetween pediatric subjects and adult subjects is equal to [ADDRESS_1280705] deviation is 0. 48ng*hr/mL for TAF AUC tau(natural log scale) estimated from 
the population PK data in Stud y GS-US-311-1089.
A total of at least 100 subjects receiving F/TAF from Cohort 1, and PartsA and B of Cohort 2 
(
Groups 1 and 2), Cohort 3, and Cohort 4 combined will provide reasonable assessment of safet y 
through Week 48inpediatric subjects .
Sample size and power calculations were made using the statistical software package nQuery  
Advisor 
(Version 7 .0) and R.
8.10. Data Monitoring Committee
An external multidisciplinary  independent data monitoring committee (IDMC) will review the 
progress of the stud y and perform interim reviews of safet y, efficacy  and PK data and provide 
recommendation to [COMPANY_009] whether the nature, frequency , and severit y of ad verse effects 
associated with study treatment warrant the earl y termination of the study  in the best interests of 
the participants, whether the study  should continue as planned, or the study should continue with 
modifications. 
The IDMC’s specific activiti es will be defined in an approved charter, which will define the 
IDMC’s membership, conduct and meeting schedule.
While the I DMC will be asked to advise [COMPANY_009] regarding future conduct of the study ,including 
possible earl y study termination, [COMPANY_009] retain s final decision- making authority  on all aspects of 
the study .
F/TAF
Protocol GS -US-311-[ADDRESS_1280706] completes 
Week 48 visit or prematurely discontinue from the study drug.Efficacy  and safet y endpoints at 
Week 24 for Cohort 1 will also be anal yzed at the W eek 48 anal ysis. A PK 
analysis will also be 
performed at the Week 48 anal ysis. 
Cohort s2, 3 and 4
APK anal ysis will be performed after all the subjects enrolled in Part A complete the IPK 
evaluation within each group (Cohort 2) or each cohort (Cohorts 3 and 4) . After the confirmation 
of TAF dose and TAF safety  acceptance among the subjects in Part A, enrollment in Part B will 
be ini tiated . 
The Week [ADDRESS_1280707] completes
Week 24 visit or prematurely discontinue from the study  drug within each group (Cohort 2) or 
cohort (Cohorts 3 and 4) .The Week [ADDRESS_1280708] completes Week 48 visit or prematurely  discontinue from the study  drug within each 
group (Cohort 2) or cohort (Cohorts 3 and 4) .
Final anal ysis will be performed after all subjects complete the study  or prematurely  discontinue 
from the study .
8.12. Endpoint Adjudication Committee
No formal endpoint adjudication committee is planned for this study .
F/TAF
Protocol GS -US-311-[ADDRESS_1280709] [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, wh ichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic pr inciples of Good Clinical Practice, as 
outlined in 21 CFR Part 312, S ubpart D, “Responsibilities of Sponsors and I nvestigators,” 
[ADDRESS_1280710] be provided prior to the 
investigator’s (and an y subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_1280711] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompany ing material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an institutional review board or independent ethics committee . The 
investigator will not begin any  study  subject activities until approval from the IRB/IE Chas been 
documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/ICE detailing any modifications made to the protocol or any  accompany ing material to 
be provided to the subject after initial approval, with the exception of those necessary  to reduce 
immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current or approved consent form for documenting written 
F/TAF
Protocol GS -US-311-[ADDRESS_1280712] 2017informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject or the subject’s legally authorized representative and the person
conducting the consent discussion, and also by  [CONTACT_122044]. 
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthor ized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, or laboratory .Laboratory  specimens must 
be label ed in such a way  as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions .NOTE :The investigator must keep a 
screening log showing codes, names, and addresses for all subject s screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, CRF /eCRF , the IMP, and an y other study information, 
remain the sole and exclusive propert y of [COMPANY_009] during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents dire ctly 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These do cuments should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, and 
governmental app roval with correspondence, informed consent, drug records, staff curriculum 
vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
inform ation for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, i.e.
, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documenta tion of the reason(s) a consented subject is not enrolled
F/TAF
Protocol GS -US-311-[ADDRESS_1280713] 2017Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results 
of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severi ty);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_1280714] approval of a marketing application in 
an ICH region ( i.e., [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_1280715] visit to enable the sponsor to perform central monitoring 
of safet y data. Subsequent to data entry , a stud y monitor will perform source data verification 
within the EDC sy stem. Original entries as well as any  changes to data fields will be stored in the 
audit trail of the sy stem.
F/TAF
Protocol GS -US-311-[ADDRESS_1280716] 2017Prior to database lock (or any  interim time points as described in the c linical data management 
plan), the investigator will use his/her log in credentials to confirm that the forms have been 
reviewed, and that the entries accurately reflect the information in the source documents.
System -generated or manual queries will be is sued to the investigative site staff as data 
discrepancies are identified by  [CONTACT_110105], who routinely  review the data 
for completeness, correctness, and consisten cy. 
The site coordinator is responsible for responding to the quer ies in a timely  manner, within the 
system, either b y confirming the data as correct or updating the original entry , and providing the 
reason for the update (e.g. data entry  error). At the conclusion of the trial, [COMPANY_009] will provide the 
site with a read-only  archive copy  ofthe data entered by  [CONTACT_10867]. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.[ADDRESS_1280717] Accountability and Return
The study  monitor will provide instructions for return to the designated disposal site . If return is 
not possible, the study  monitor will evaluate each study  center’s IMP disposal procedures and 
provide appropriate instruction for destruction of unused IMP supplies. If the site has an 
appropriate s tandard operating procedure (SOP) for drug destruction as determined by  [CONTACT_199623]
, the site may  destro y used (empt yor partially  empty ) and unused IMP supplies in accordance 
with th atsite’s approved SOP. A copy  of the site’s approved SOP will be obtained for central 
files. 
If IMP is destro yed on site, the investigator must maintain accurate records for all IMP
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copi[INVESTIGATOR_143346]. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The in
vestigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y monitors , or to regulatory authorit y or health authority  inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.
F/TAF
Protocol GS -US-311-[ADDRESS_1280718] submit a ll protocol modifications to the in 
accordance with local requirements
and receive documented approval before modifications can 
be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency . [COMPANY_009] will 
ensure that the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least [ADDRESS_1280719] 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4 ).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed ne cessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and an y other transfer of value.
F/TAF
Protocol GS -US-311-[ADDRESS_1280720] access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF /eCRF .
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on them. The monitor should have access to any subject records needed to 
verify  the entries on the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilea
d medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
F/TAF
Protocol GS -US-311-[ADDRESS_1280721] 201710. REFERENCES
Capeau J. Premature Aging and Premature Age- Related Comorbidities in HIV -Infected Patients: 
Facts and Hy pothes es. Clin I nfect Dis 2011;53 (11):1127 -9.
Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral 
Agents in Pediatric Infection. Available at http://aidsinfo.nih.gov/guidelines. 
Accessed: March 14 2014.
EMTRI VA®, [COMPANY_009] Scie nces Inc. EMTRIVA®(emtricitabine) capsule, for oral use. 
EMTRI VA®(emtricitabine) oral solution. US Prescribing Information. Foster 
City, CA. Revised November.  2012:
[COMPANY_009] Sciences Inc. GENVOYA®(elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide) tablets, for oral use. US Prescribing Information. Foster City , CA 
Revised March.  2016:
[COMPANY_009] Sciences International L imited. Genvo ya 150mg/150mg/200mg/10mg film coated tablets. 
Summary  of Product Characteristics.  Updated 07 March.  2016:
Ginsberg G, Hattis D, Miller R, Sonawane B. Pediatric pharmacokinetic data: implications for 
environmental risk assessment for children. Pediatrics 2004;113 ([ADDRESS_1280722]):973 -
83.
HHS Panel on Antiretroviral Therap y and Medical Management of HIV- Infected Children with 
HIV. Guidelines for the use of Antiretroviral Agents in Pediatric HIV Infection. 
Revised: 27 April.  2017.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact Sheet 2016. Available at: 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS _FactSheet_en.pdf
.  2016.
McCarver DG. Applicability  of the principles of developmental pharmacology  to the study  of 
environmental toxicants. Pediatrics 2004;113 ([ADDRESS_1280723]):969-72.
Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. C hanging patterns of 
mortality  across Europe in patients infected with HIV- 1. EuroSIDA Study  Group. 
Lancet 1998;352 (9142):1725-30.
Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. Declining 
Morbidity  and Mortalit y Among Patients With Advanced Human 
Immunodeficiency  Virus I nfection. N Eng J Med 1998;338 (13):853-60.
F/TAF
Protocol GS -US-311-[ADDRESS_1280724] 2017Panel on Antiretroviral Therap y and Medical Management of HIV -infected Children. Guidelines 
for the use of antiretroviral agents in pediatric HIV infection: Available at: 
http://aidsinfo.nih.gov/ContentFiles/PediactricGuidelines.pdf. Accessed 
September 9, 2012.  2011:[ADDRESS_1280725] oS ONE 2011;6 (8):e17502.
Robbins BL , Greenhaw JJ, Connelly  MC, Fridland A. Metabolic pathway s for activation of the 
antiviral agent 9 -(2-phosphony lmethoxy ethyl)adenine in human ly mphoid cells. 
Antimicrob Agents Chemother 1995;39 (10):2304 -8.
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term effectiveness 
of potent antiretroviral therap y in preventing AIDS and death: a prospective 
cohort study . Lancet 2005;366 (9483):378-84.
Welch S, Sharland M, Lyall EG, Tudor -Williams G, Niehues T, Wintergerst U, et al. PENTA 
2009 guidelines for the use of antiretroviral therapy  in paediatric HIV -1 infection. 
HIV Med 2009;10 (10):591 -613.
World Health Organization (WHO). Developi[INVESTIGATOR_911713] 2.0 Priorities. 
Presented at: Paediatric Antiretroviral Working Gr oup.; 2011 25- 26 October; 
Geneva, Switzerland. 
F/TAF
Protocol GS -US-311-[ADDRESS_1280726] 201711. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appe ndix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 6. Definitions of HIV -1 Related Disease
Appendix 7. Tanner Stages
F/TAF 
Protocol GS-US-311-[ADDRESS_1280727] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitab ine/Teno fovir 
Alafenamide (F/TAF) in HIV-[ADDRESS_1280728] this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated . 
I will provi de all study personnel under my supervision copi[INVESTIGATOR_911714], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_279395] 89 02August2017 
F/TAF
Protocol GS -US-311-[ADDRESS_1280729] 2017Appendix 2. Study Procedures Table
Study Procedure ScreencBaseline/ 
Day 1dEnd of WeekaPost Week 48b
30 Day 
Follow -upeESDDf1 2 4 8 12 24 36 48Every 
12WksEvery 
24Wks
Informed Consent/Assent X
Medical HistorygX
Concomitant Medications X X X X X X X X X X X X X
Adverse Events X X X X X X X X X X X X X
Com plete Physical Exam X X X X XhX
Symptom -Directed Physical ExamiX X X X X X X X
12-Lead ECG (performed supi[INVESTIGATOR_050]) X XjX
Vital Signs X X X X X X X X X X X X X
Weight and Height /Length X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X
Urine Chemistry X X X X X X X X X
Selected R enal Safety TestskX X X X X X X X Xl
Serum Pregnancy TestmX
Urine Pregnancy TestnX X X X X X X X X X X X
Chemistry Profile X X X X X X X X X X X X X
Metabolic Assessments X X X X
Estimated GF R X X X X X X X X X X X X X
Hem atology Profile X X X X X X X X X X X X X
Plasma HIV- 1 RNA X X X X X X X X X X X X X
CCI
F/TAF
Protocol GS -US-311-[ADDRESS_1280730] 2017Study Procedure ScreencBaseline/ 
Day 1dEnd of WeekaPost Week 48b
30 Day 
Follow -upeESDDf1 2 4 8 12 24 36 48Every 
12WksEvery 
24Wks
CD4+ Cell Count X X X X X X X X X X X X X
Whole Blood Sample Storage X
Serum Storage Sample X X
HCV SerologypX
HBV Serology X
EnrollmentqX
Cohort 1 Dispense Diary CardsrX
Cohort s 2, 3, & 4 Dispense Diary 
Cardsr X X
Single Random  PK S amplesX X
Cohorts 1 and 2 Fasted Prior to Visit X X X X X X X X
Cohort 1 IPK SamplingtX
Cohort 2 Part A IPK SamplingtXtXt
Cohort 1 Palatabilit yand 
Acceptability Assessmentu X XuXu
Cohort 2 Part A Palatabilit yand 
Acceptability AssessmentX X
Single Observed Dosing PKSamplevX X
Trough PK Samples,wX
PBMCs,xX
DXA Scan (spi[INVESTIGATOR_050] & total body ) X X X X XyXy
CCI
F/TAF
Protocol GS -US-311-[ADDRESS_1280731] 2017Study Procedure ScreencBaseline/ 
Day 1dEnd of WeekaPost Week 48b
30 Day 
Follow -upeESDDf1 2 4 8 12 24 36 48Every 
12WksEvery 
24Wks
Cohort 1 Serum Bone Safety TestszX X X X X X Xaa
Cohort s 2, 3, and 4 Serum Bone 
Safety Testsz X X X X X X Xaa
Tanner Stage AssessmentbbX X X X
In-Clinic Dosing X X X X
Study Drug Dispensation X X X X X X X Xcc
Study Drug Accountability X X X X X X X X X X
a All study visits are to be scheduled relative to when the Baseline/Day 1 visit was completed. All study visits through Week 8 are to be completed within ± 2 days of the 
protocol-specified visit date. Visits between Week 12 through Week 48 are to be completed within ± [ADDRESS_1280732] Week 48 study visits are to be completed every 12 weeks ( ±10days)unless otherwise specified .
c All screening e valuations are to be completed within 35 days prior to Baseline/ Day 1 Visit.
d Subjects will be dispensed study drug on the Baseline/ Day [ADDRESS_1280733] within 24 hours after the Baseline/ Day 1 visit. 
F/TAF will be provided by [CONTACT_911732].
e [ADDRESS_1280734] one subsequent visit after the Early Study Drug Discontinuation (ESDD) Visit. For the purpose of scheduling a 30-Day Follow -Up 
Visit, a ± 6days window may be used.
f Early Study Drug Discontinuation visit to occur within [ADDRESS_1280735] 48 weeks (urogenital/anorectal exams will be performed at the discretion of the Investigator).
i Symptom -directed physical examination ,as needed.
j 12-lead ECG performed supi[INVESTIGATOR_911706] [ADDRESS_1280736] was > [ADDRESS_1280737]’s enrollment number may occur up to 7 days prior to the Baseline/Day 1 visit.
CCI
F/TAF
Protocol GS -US-311-[ADDRESS_1280738] dose.
t IPK will occur during the Week 2 visit for subjects in Cohort 1 and at either the Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits, for 
subjects in Cohort 2 Part A. For the purpose of schedul ing the IPK visit, a + [ADDRESS_1280739] observed in -clinic dose. For subjects in Cohort 2 Part A, 
a single observed dosing PK sample does not need to be collected at Week 4 if IPK is collected at the Week 4 visit.
w For subjects in all Cohort s atrough PK sample will be collected during the Week 8 visit at 0hours (pre-dose, ≤ 30 minutes prior to dosing) wil l be collected. 
x For subjects in Cohort s1 and 2 ,PBMC collection will be performed atthe Week 8 visit only at study sites that can perform PBMC processing. For subjects in 
Cohort s 3and4,PBMC collection schedule will be specified in a future protocol amendment. All PBMC blood samples will be collected at 0 hours (≤ 30 minutes pre -dose) .
y DXA scan to be performed at the [ADDRESS_1280740] scan was acquired > [ADDRESS_1280741] was > 12 weeks from ESDD visit.
bb Tanner assessments will be performed at Baseline/Day1, Weeks [ADDRESS_1280742] Week 48.
F/TAF
Protocol GS -US-311-[ADDRESS_1280743] 2017Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade 1Grade 4 Grade 3 Grade 2
May continue 
dosing at the 
discretion of the 
investigatorRepeat lab to 
confirm  toxicity 
gradeRepe t lab t  
confirm  toxicity 
grade
If confirm ed and possibly and/or probably related to 
investigational m edicinal products:
1.Withhold investigational m edicinal products until Grade [ADDRESS_1280744] 
weekly until a return 
to baseline or is 
otherwise explained
If Grade 3 or 4 recurrence that is confirm ed and p ossibly or 
probably related to investigational m edicinal products, 
discontinue all investigational m edicinal products dosing 
perm anently Grade 3 or 4 recurrence that is considered unrelated to 
investigational m edicinal products, continue all investiga tional 
medicinal products at the same dose at the discretion of the 
investigator    
     ----l --  
   
  
   
F/TAF
Protocol GS -US-311-[ADDRESS_1280745] 2017Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Version :18 June 2012
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 7Days1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Infant , 2 –7 Days 1250 to 1500/mm3
1.25 to1.50 GI/L1000 to 1250/mm3
1.00 to< 1.25 GI/L750 to 1000/mm3
0.75 to< 1.00 GI/L750/mm3
< 0.75 GI/L
Infant , 1 Day 4000 to 5000/mm3
4.00 to5.00 GI/L3000 to 4000/mm3
3.00 to < 4.00 GI/L1500 to 3000/mm3
1.50 to< 3.00 GI/L1500/mm3
< 1.50 GI/L
F/TAF
Protocol GS -US-311-[ADDRESS_1280746] 2017HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Norm alized Ratio 
of prothrombin time (INR)1.[ADDRESS_1280747] >1.[ADDRESS_1280748] >2.[ADDRESS_1280749] >3.[ADDRESS_1280750]
Activated Partial
Thromboplastin Time (APTT)1.00 to 1.66ULN 1.66 to 2.33ULN 2.33 to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0%
F/TAF
Protocol GS -US-311-[ADDRESS_1280751] 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia 146  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
146  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 3.0 to 3.4 mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to 3.4 mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Hyperkalemia 5.6 to 6.0 mEq/L 6.0 to 6.5 mEq/L 6.5 to 7.0 mEq/L 7.0 mEq/L
5.6 to 6.0 mmol/L 6.0 to 6.5 mmol/L 6.5 to 7.0 mmol/L 7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL 40 to55mg/d L 30 to40mg/d L 30 mg/dL
3.03 to 3.58 mmol/L 2.20 to3.03 mmol/L 1.64 to2.20 mmol/L 1.64 mmol/L
Infant,1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate* )
Adult and Pediatric
7Days7.8 to 8.4  mg/dL 7.0 to7.8 mg/dL 6.1 to7.0mg/dL 6.1mg/d L
1.94 to 2.10 mmol/L 1.74 to1.94 mmol/L 1.51 to1.74 mmol/L 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate* )
Adult and Pediatric
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
F/TAF
Protocol GS -US-311-[ADDRESS_1280752] 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmo l/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL 1.5 to2.0 mg/dL 1.0 to1.5 mg/dL 1.0 mg/dL
0.63  to LLN mmol/L 0.47 to0.63 mmol/L 0.31 to0.47 mmol/L 0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to 3.5 mg/dL
0.96 to 1.1 2mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to 4.5 mg/dL
1.12 to 1.46 mmol/L2.5 to 3.5mg/dL
0.80 to <1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia 1.5 mg/dL to LLN 1.0 to1.5 mg/dL 0.5 to1.0 mg/dL 0.5 mg/dL
87 μmol/L to LLN 57 to87 μmol/L 27 to57 μmol/L 27 μmol/L
Creatinine 1.50to 2.00 mg/dL 2.00to 3.00 mg/dL 3.00 to 6. 00 mg/dL 6.00 mg/dL
133to 177μmol/L 177to 26 5 μmol/L 265to 530 μmol/L 530 μ mol/L
F/TAF
Protocol GS -US-311-[ADDRESS_1280753] 2017CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Bicarbonate 16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL 750 to 1200 mg/dL 1200 mg/dL
5.64–8.47 mmol/L 8.47–13.55 mmol/L 13.55 mmol/L
LDL
(Fasting)130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
Pediatric >2 to <18 years 110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/d L NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calc ium should be cor rected for albumin if albumin is < 4.0 g/dL
ENZYMES
Grade [ADDRESS_1280754] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin 3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
F/TAF
Protocol GS -US-311-[ADDRESS_1280755] 2017URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999mg/24 h >999 to1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499mg/m2/24h >499 to799mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Note s: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratorie s, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
F/TAF
Protocol GS -US-311-[ADDRESS_1280756] 2017CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac A rrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/I nfarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (wit h repeat 
testing at same visit)140– 159mmH g systolic 
OR 
90–99 mmH g diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(e.g., malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(e.g., malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial E ffusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusi on requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with non-urgent intervention 
indicatedLife-threatening consequences 
(e.g., tamponade) OR Urgent 
intervention indicated
F/TAF
Protocol GS -US-311-[ADDRESS_1280757] 2017CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric [ADDRESS_1280758] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baselineLife-threatening 
consequences, e.g., Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, e.g., Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/E mbolism NA Deep vein thrombosis AND 
No intervention indicated 
(e.g., anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated ( e.g., 
anticoagulation, lysis filter, 
invasive procedure) Embolic event ( e.g., 
pulmonary embolism, life -
threatening thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
F/TAF
Protocol GS -US-311-[ADDRESS_1280759] 2017RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_422258]/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
F/TAF
Protocol GS -US-311-[ADDRESS_1280760] 2017SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
[CONTACT_10872] (for disabled 
adults)Thinning or patchy hair loss 
detectable by [CONTACT_110106] – Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
F/TAF
Protocol GS -US-311-[ADDRESS_1280761] 2017GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetit e without 
decreased oral intakeLoss of appetite associated with 
decreased oral intake w ithout 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [ e.g., tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated ( e.g., diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(e.g., sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(e.g., obstruction)
Diarrhea 
Adult and Pediatric 
1 YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hrPersistent epi[INVESTIGATOR_10813] 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(e.g., hypotensive shock)
Pediatric 1 Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration
indicated OR Hypotensive 
shock
F/TAF
Protocol GS -US-311-[ADDRESS_1280762] 2017GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
Mucositis/S tomatitis 
(clinical exam)
See also Pr octitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences ( e.g., aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated ( e.g., 
IVfluids)Life-threatening consequences 
(e.g., hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(e.g., sepsis, circulatory 
failure, hemorrhage)
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfor t AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(e.g., perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent epi[INVESTIGATOR_911715]-threatening consequences 
(e.g., hypotensive shock)
F/TAF
Protocol GS -US-311-[ADDRESS_1280763] 2017NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in M ood ( e.g., 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others ( e.g., 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dem entia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional ac tivities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive a nd 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & funct ional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual socia l & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate 
for the settingModerate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting
F/TAF
Protocol GS -US-311-[ADDRESS_1280764] 2017NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or 
other neurologic function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perfo rm usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptoma tic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & 
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sensory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive ( e.g., 
status epi[INVESTIGATOR_7397]), or difficult 
to control ( e.g., refractory 
epi[INVESTIGATOR_002])
F/TAF
Protocol GS -US-311-[ADDRESS_1280765] 2017NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_911716] o f 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure cha racter 
from baseline either in 
duration or quality ( e.g., 
severity or focality) Seizures of any kind that are 
prolonged, repetitive ( e.g., 
status epi[INVESTIGATOR_7397]), or difficult 
to control ( e.g., refractory 
epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 Y earsSeizure, generalized onset 
with or without second ary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< [ADDRESS_1280766] ictal stateSeizure, generalize d onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling ve rtigo causing 
inability to perform basic self -
care functions
F/TAF
Protocol GS -US-311-[ADDRESS_1280767] 2017MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform ba sic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
F/TAF
Protocol GS -US-311-[ADDRESS_1280768] 2017SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralize d urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/ malaise 
symptoms causing inability to 
perfo rm basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain- Indicate Body  Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and My algiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [ e.g., 
tube feeding or total parenteral 
nutrition]
F/TAF
Protocol GS -US-311-[ADDRESS_1280769] 2017INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site P ain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tend erness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basic self -care 
function OR Hospi[INVESTIGATOR_059] 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (invo lving dermis and 
deeper tissue)
Pediatric 15Years Erythema OR Induration 
OR Edema present but 
2.5cm diameterErythema OR Induration OR 
Edema > 2.5cm diam eter but 
<50% surface area of the 
extremity segment ( e.g., upper 
arm/thigh)Erythema OR Induration 
OR Edema involving 50% 
surface area of the extremity 
segment ( e.g., upper 
arm/thigh) OR Ulceration 
OR Secondary infection OR 
Phlebitis OR Sterile abscess 
OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
F/TAF
Protocol GS -US-311-[ADDRESS_1280770] 2017ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( e.g., back 
of neck, breasts, 
abdomen)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_110107][INVESTIGATOR_10820]-threatening consequences 
(e.g., ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10876] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences
(e.g., thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social &
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(e.g., myxedema coma)
Lipoatrophy ( e.g., fat loss 
from the face, extremities, 
buttocks)Detectable by [CONTACT_10874] 
(for young children a nd 
disabled adults)Detectable on physical exam by 
[CONTACT_236726]
F/TAF
Protocol GS -US-311-[ADDRESS_1280771] 2017GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by [CONTACT_110108] -
threatening hypotension OR 
Operative intervention 
indicated
Urinary T ract 
obstruction ( e.g., stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing 
life-threatening 
consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic anti μbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic anti μbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic anti μbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences ( e.g., septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a hobby, e tc.
F/TAF
Protocol GS -US-311-[ADDRESS_1280772] 2017Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Pregnancy and Contraception Requirements for Males and Females of Childbearing 
Potential 
The risks of treatment with the study  drug during pr egnancy  have not been evaluated. 
Pregnancy  
must be excluded before the start of treatment with study  drug and prevented thereafter b y 
reliable contraceptive methods. Pregnancy  tests will be performed regularly throughout this 
study  (Refer 
to Appendix 2). If females are using hormonal agents for contraception, the safet y 
and/or efficacy  may  be affected b y possible drug
-drug interaction. However, it is recommended 
that the hormonal agent be continued and that a non-hormonal method (or methods) be used 
concurrently .
If females utilize hormonal agents as one of their contraceptive m ethods, it is required that the 
same hormonal method be used for at least [ADDRESS_1280773] version of the Investigator’s Brochure for additional informatio n.
2)Definition of Female of Childbearing Potential
For the pur poses of this study , a female subject of childbearing potential is a nonmenopausal 
female who has not had a hy sterectom y, bilateral oophorectom y, or medically  documented 
ovarian failure. A woman who has had a tubal sterilization is considered to be of chil dbearing 
potential. This definition alsoincludes a pubertal female who has not yet started menstruating. 
A female subject may  be considered m enopaus alineither of the following conditions:
Surgical menopause: Appropriate medical documentation of prior c omplete bilateral 
oophorectom y (i.e., surgical removal of the ovaries and occurring at the age at which the 
procedure was performed)
Spontaneous menopause: Permanent cessation of previously occurring menses as a result of 
ovarian failure with documentation of hormonal deficiency  by a certified health care 
provider . The worldwide mean age of spontaneous menopause is 49.24 (SD1.73) years
3)Contraceptive Requirements 
Female subjects of childbearing potential who engage in intercourse must agree to utilize 
protocol specified methods of contraception from the s creening visit throughout the study  period 
and for 30days following the last dose of study  drug. 
Male subjects of childbearing potential 
who engage in intercourse must agree to utilize protocol specified methods of contraception from 
the e nrollment visit throughout the study  period and for 30days following the last dose of study  
drug. 
Female stud y subjects who are not heterosexually active must provide periodic confirmation of 
continued abstinence from heterosexual intercourse and regular pregnancy testing while taking 
any study  medication . The investigator will counsel subjects on the protocol specified method(s) 
for avoiding pregnancy  in case the subject chooses to engage in heterosexual intercourse.
F/TAF
Protocol GS -US-311-[ADDRESS_1280774] 2017Protocol specified contraceptive methods are as follows: 
1) a combination of one hormonal method and one barrier method; 
2)two barrier metho ds where one method is the male condom; 
3) use of an intrauterine device (IUD) or tubal sterilization; 
See Appendix Table 1below. Acceptable hormonal methods include injectable progesterone, 
progesterone implants, combination oral contraceptives, transderm al contraceptive patch, and 
vaginal ring. Acceptable barrier methods include diaphragm with spermicide, cervical cap with 
spermicide, and the male condom. 
Female subjects must use either a hormonal method or a barrier method if the partner has a 
vasectom y. If a subject has undergone tubal sterilization or has had a Copper T 380A IUD or 
LNg 20 IUD inserted, no other contraception is needed.
If tubal sterilization is via the Essure procedure, verification of tubal blockage b y 
hysterosalpi[INVESTIGATOR_8913] (HSP) must be performed approximately  [ADDRESS_1280775] at B aseline /Day [ADDRESS_1280776] discontinue nursing before IMP administration.
Appendix Table 1.Protocol Specified Contraceptive Methods
Methods to Use by [CONTACT_409767]
(choose one and use with a 
barrier method)Barrier Methods
(use both OR choose one and use 
with a horm one method)
Intrauterine Devices (IUDs)
Copper T 380A IUD
LNg 20 IUD
Tubal SterilizationEstrogen and Progesterone
Oral contraceptives
Transdermal patch
Vaginal ring
Progesterone
Injection
ImplantDiaphragm with spermicide
OR
Cervical cap with spermicide
Male condom (without 
spermicide)
Partner’s vasectomy must be used with a hormone or barrier method.
F/TAF
Protocol GS -US-311-[ADDRESS_1280777] effective method(s) for avoiding pregnancy  
during the stud y.
Male subjects must agree to use condoms during heterosexual intercourse and avoid sperm 
donation while enrolled in the study  and for at least [ADDRESS_1280778]’s partner is infected with HI V.
4)
Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the i nvestigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30days of last study  drug dose .
Subjects who become pregnant or who suspect that they are pregnant during the stud ymust 
report the information to the investigator and seek the investigator’s advice regarding action 
required wi th the study  drug immediatel y. 
Instructions for reporting pregnancy and pregnancy  outcome are outlined in Section [IP_ADDRESS].
F/TAF
Protocol GS -US-311-[ADDRESS_1280779] 2017Appendix 6. Definitions of HIV -1 Related Disease
CDC Classification Sy stems, Category  C: AIDS -
Indicator Conditions
Bacterial pneumonia, recurrent (two or more epi[INVESTIGATOR_11630] 12 months)
Candidiasis of bronchi, trachea, or lungs
Candidiasis, esophageal
Cervical carcinoma , invasive , confirmed b y biopsy
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal ( 1month duration)
Cytomegalovirus disease (other than liver, spleen or nodes)
Encephalopath y, HIV -related
Herpes simplex: chronic ulcers ( 1month duration) ,or bronchitis, pneumonitis or 
esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal ( 1-month duration)
Kaposi’s sarcoma
Lym phoma, Burkitt , immunoblas
tic, or primary  central nervous s ystem
Mycobacterium avium complex (MAC) or Myobacterium kansasii , disseminated or 
extrapulmonary
Mycobacterium tuberculosis , pulmonary  or extrapulmonary  
Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
Pneumocystis jirovecii (formerl y carinii )pneumonia (PCP)
Progressive multifocal leukoencephalopathy (PML)
Salmonella septicemia, recurrent (nont yphoid)
F/TAF
Protocol GS -US-311-[ADDRESS_1280780] 2017Toxoplasmosis of brain
Wasting syndrome caused by [CONTACT_10840] (involuntary  weight loss > 10% of baseline weight) 
associated with either chronic diarrhea (two or more loose stools per day  for ≥ 1month) or 
chronic weakness and documented fever for ≥ 1 month
U.S Department of Health and Human Services (DHHS). Guide for HIV/AIDS Clinical Care. -
2014 {Department of Health and Human Services (DHHS) 2014 }
F/TAF
Protocol GS -US-311-[ADDRESS_1280781] 2017Appendix 7. Tanner Stages
1. Pubic hair (m
ale and female)
Tanner I no pubic hair at all (prepubertal Dominic state)
Tanner IIsmall am ount of long, dow ny hair with slight pi[INVESTIGATOR_648449] 
(males) or on the labia majora (females)
Tanner III hair becomes more coarse and curly, and begins to extend laterally
Tanner IV adult -like hair quality, extending across pubis but sparing medial thighs
Tanner V hair extends to medial surface of the thighs
2. Genitals (m ale) (One standard deviation around m ean age)
Tanner I Testes, scrotum, and penis about same size and proportion as in early childhood
Tanner IIEnlargement of scrotum and testes; skin of scrotum reddens and changes in texture; little or no 
enlargement of penis (10.5 -12.5)
Tanner III Enlargement of penis, first mainly in length; further grow th of testes and scrotum (11.5 -14)
Tanner IVIncreased size of penis with grow th in breadth and development of glans; further enlargement of 
testes and scrotum and increased darkening of scrotal skin (13.5 -15)
Tanner V Genitalia adult in size and shape
3. Breasts (fem ale)
Tanner I no glandular tissue: areola follow s the skin contours of the chest
Tanner II breast bud forms, with small area of surrounding glandular tissue; areola begins to widen
Tanner IIIbreast begins to become more elevated, and extends beyond the borders of the areola, w hich 
continues to widen but remains in contour with surrounding breast
Tanner IVincreased breast size and elevation; areola and papi[INVESTIGATOR_141878] a secondary mound projecting from 
the contour of the surrounding breas t
Tanner Vbreast reaches final adult size; areola returns to contour of the surrounding breast, w ith a 
projecting central papi[INVESTIGATOR_9387].